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Abstract
Breast cancer is the most common malignancy in women and accounts for more
than 400,000 deaths per year worldwide. Oestrogen receptor α -positive (ER+)
tumours account for approximately 80% of all breast tumours. A breast cancer
susceptibility locus at 6q25.1, identified by the use of genome wide association
studies (GWAS), is located directly upstream of the ESR1 gene that encodes
the oestrogen receptor (Zheng et al., 2009). Three genes that are co-expressed
with the ESR1 gene - ARMT1, CCDC170 and RMND1 - lie within this breast
cancer susceptibility locus (Dunbier et al., 2011). Recent studies have shown
a link between ARMT1 and the susceptibility and progression of ER+ breast
tumours Yamamoto-Ibusuki et al., 2015).
To investigate the function of ARMT1, MCF-7 cells with ARMT1 knock-
down by stably transfected shRNA, and ARMT1 over expression by stable trans-
fection with pDHA-neo-ARMT1 were obtained. After validation of these clones
by qPCR and western blotting techniques, doubling time analysis showed no dif-
ference between either the ARMT1 knockdown and over expression clones and
their respective controls, suggesting there is not a direct link between ARMT1
i
and proliferation rate. Similarly, no difference was seen between the knockdown
clones and their controls when senescence-associated β -galactosidase activity
was assessed, before and after the cells were exposed to DNA damage and stress,
suggesting ARMT1 levels do not affect senescence induction in these clones.
Again no difference was observed when the clones were analysed for anchor-
age independent growth, indicating ARMT1 is not involved with the evading
of growth suppressors. Cell wounding assays produced a significant increase in
migration in the ARMT1 overexpression clones compared to a control, however
no significant differences were seen between the ARMT1 knockdown clones and
controls. DNA damage response was analysed via clonogenic growth of cells af-
ter exposure to doxorubicin and UV. Small differences in survival between the
knockdown and over expression clones and their respective controls were ob-
served, but the magnitude of these changes was inconsistent with previous find-
ings (Perry et al., 2015).
Interestingly, expression analysis with qPCR revealed reduced expression
of ESR1 in ARMT1 knockdown clones. This expression pattern is mirrored by
CCDC170, RMND1, and the oestrogen responsive genes TFF1 and GREB. Cu-
mulatively these results suggest ARMT1 may have a role in regulating ESR1
expression. Further analysis is needed however to investigate the mechanism
through which this occurs.
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Breast cancer is the most common malignancy in women globally with an esti-
mated 1.67 million new cases diagnosed in 2012 (Gonzalez et al., 2015; Mathers
et al., 2008). It is estimated that one in eight women in westernised countries
will develop breast cancer within their lifetime, with the highest rates per capita
in Western and Northern Europe, Australia, New Zealand, and North Amer-
ica (Siegel et al., 2009). This complex multifactorial disease is responsible for
more than 400,000 deaths per year worldwide, making it the leading cause of
death by cancer in women (Gonzalez et al., 2015; Zheng et al., 2009). In New
Zealand, breast cancer accounts for 28.7% of all new cancer registrations, and
approximately 16% of cancer deaths (Ministry of Health, 2013). The incidence
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and mortality rates are indicative of the overwhelming need for a better under-
standing of the biological mechanisms of the disease, in order to improve clinical
outcomes for patients.
Environmental factors and an ageing population have been associated with
an increase in breast cancer cases, along with several identified risk factors such
as high fat intake, obesity, alcohol intake, parity, oral contraceptives, and hor-
mone replacement therapies (Allen et al., 2009; Cleary and Grossmann, 2009;
Lund et al., 2007). Conversely, pregnancy has been shown to give a protective
effect against breast cancer. Giving birth by the age of 20 can reduce the risk of
developing oestrogen or progesterone dependent breast cancer by 50% in women,
with subsequent births increasing this protective effect (Britt et al., 2007). The
general tendency in westernised countries to have children later in life along
with increased use and exposure to the aforementioned risk factors are thought
to contribute to the increased prevalence of breast cancer in these countries.
1.1.1 Breast cancer classification
A key discovery for the treatment of breast cancer came from the recognition
of the role of hormones in many breast cancers. The first insight into this came
from Cooper and Beatson when they correlated phases of the menstrual cycle
with size of breast tumour, and showed tumour regression and improved progno-
sis could be achieved by an ovariectomy (Beatson, 1898; Cooper, 1836).
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Breast cancer is now often regarded as a collection of separate diseases
due to the heterogeneous nature of the disease (Bertucci et al., 2012; Prat and
Perou, 2011). Breast tumours are diverse in their responsiveness to currently
available treatments, leading to their classification into molecular subtypes dis-
tinguished by the differences in their gene expression patterns (Perou et al.,
2000). Subtyping of breast cancers is necessary in order to optimise prognostic,
predictive and therapeutic targets (Bertucci et al., 2012).
The use of classic pathological techniques based on overall morphology and
structural organisation has allowed the characterisation of breast tumours into
histological subtypes (Bertos and Park, 2011; Weigelt et al., 2008). Invasive
ductal carcinomas, which account for approximately 75% of all observed and
reported tumours, together with invasive lobular carcinomas, which account
for another 10%, make up the vast majority of breast cancers. The remaining
15% are categorised as medullary, neuroendocrine, tubular, apocrine, metaplas-
tic, mucinous, inflammatory, comedo, adenoid cystic, and micropapillary types
(Bertos and Park, 2011).
1.1.2 Breast cancer subtypes
The detection of biomarkers and unique gene expression profiles has allowed
further molecular subtyping. The most commonly accepted and reproducibly
found molecular subtypes are luminal A, luminal B, human epidermal growth
factor receptor 2+ (HER2+) and basal-like (Bertucci et al., 2012; Prat and
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Perou, 2011; Schnitt, 2010). Each of these subtypes differ in their risk factors,
incidence, response to treatment, progression and preferential metastatic sites
(Polyak, 2011).
Luminal A and luminal B are identified as hormone receptor positive tu-
mours and generally respond well to hormonal treatments. Luminal A tumours
are positive for both oestrogen and progesterone receptors, with luminal B tu-
mours positive for only oestrogen receptors (Polyak, 2011; Schnitt, 2010). Lu-
minal A is the most common breast cancer subtype, accounting for 50-60% of
all breast tumours. They express both the oestrogen and progesterone recep-
tor, and are typically of low grade, with a low rate of proliferation. This usually
equates to a good prognosis and a lower relapse rate compared to other subtypes
(Eroles et al., 2012; Kennecke et al., 2010; Weigelt et al., 2009).
Luminal B cancers are typically more aggressive that Luminal A cancers
and represent 10-20% of breast tumours. They have both a higher prolifera-
tion rate and histological grade, and also express additional markers, epidermal
growth factor (EGFR) and human epidermal growth factor 2(HER2) (Eroles et
al., 2012). Luminal B tumours present with a poorer prognosis than Luminal A
tumours, but respond better to neoadjuvant chemotherapy, allowing a greater
proportion to achieve a pathological complete response (Eroles et al., 2012; von
Minchwitz et al., 2012).
HER2+ tumours express amplified levels of the HER2 gene, thus leading
to increased levels of the growth factor and causing increased proliferation and
high histological grade (Eroles et al., 2012; Slamon et al., 2001). HER2+ tu-
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mours represent 15-20% all breast tumours, however considerable heterogeneity
exists within the subtype (Eroles et al., 2012). The factors are associated with
HER2+ tumours being aggressive, having decreased disease-free survival periods
and overall survival rates (Slamon et al., 2001).
Basal-like tumours are also called triple negative breast cancer (TNBC),
as they lack both oestrogen and progesterone receptors, and HER2 expression
(Polyak, 2011; Rakha et al., 2008). These tumours are driven primarily by ex-
pression of genes characteristic of basal myoepithelial cells and luminal epithelial
cells, generally making the tumours large with a high histological grade (Eroles
et al., 2012). Although these tumours respond well to chemotherapy initially,
they have a high rate of recurrence and death within five years of diagnosis
(Dowsett et al., 2006).
1.1.3 Oestrogen receptor positive breast cancer
Oestrogen receptor (ER) status is arguably the most clinically important biolog-
ical factor in oncology (Dunbier et al., 2011). Approximately 80% of all breast
tumours present as oestrogen receptor α-positive (ER+) tumours, with oestro-
gen being the main stimulant in the development and growth of these tumours
(Johnston and Dowsett, 2003). Oestrogens are steroid hormones that regulate
differentiation, proliferation and growth in both normal and malignant breast
cells (Hovey and Trott, 2004; Sommer and Fuqua, 2001). As hormones are the
driving force behind mammary morphogenesis, disruption to the processes gov-
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erning the sensitivity and exposure of hormones can lead to them driving mam-
mary carcinogenesis.
Two nuclear receptors exist for the principal oestrogen hormone, 17-β-oestradiol;
ERα, encoded by ESR1 located on chromosome 6 (hereafter ER), and ERβ, en-
coded by ESR2 on chromosome 14 (Anderson, 2002; Griekspor et al., 2007).
Both are ligand-dependent nuclear transcription factors that are homologous
in their DNA-binding and steroid-binding domains, however the ERβ gene is
smaller, encodes a shorter protein, and has a different chromosomal position
(Anderson, 2002). Studies suggest ER drives the proliferative effects of oestro-
gen, whereas ERβ represses proliferation and is pro-apoptotic (Thomas and
Gustafsson, 2011). Recent studies investigating the two receptors during the
transition of normal breast cells to carcinoma cells saw an increase in the num-
ber of ER positive (ER+) cells, and a decrease in the number of ERβ positive
cells (Huang et al., 2014). Consequently, the presence of ER can be regarded as
a good indicator for successful endocrine therapy, whereas a decrease in ER is
indicative of poor therapeutic outcomes (Herynk and Fuqua, 2007). The dysreg-
ulation of ER expression occurs in the earliest stages of breast cancer, increasing
its expression so that the normal relationship between cell proliferation and re-
ceptor expression is lost (Anderson, 2002).
Further studies into ER have elucidated much about its action. In the late
1980’s, the gene encoding the ER protein was isolated from MCF-7 cells and
subsequently studied. The structural domains of the receptor were identified,
leading to the identification of ER as a ligand-dependent transcription factor
(TF) (Green et al., 1986; Greene et al., 1986; Walter et al., 1985). This impor-
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tant finding led to the interpretation that genetics must be responsible for oe-
strogen sensitivity, thus contributing to mammary cell phenotype. Further re-
search confirmed this, showing genetic factors along with co-regulators modulate
the transcriptional activities driven by ERs (Carroll and Brown, 2006; Marino
et al., 2006; Wall et al., 2014; Welboren et al., 2009). These co-regulators found
in hormone receptor positive cells by Onate et al. (1995) represent a class of
regulatory proteins with co-repressors and co-activators. Being differentially
recruited by the ERs, they activate or suppress subgroups of genes in different
functional combinations, thus ’fine-tuning’ gene expression, ultimately contribut-
ing to tumourigenicity.
1.1.3.1 ER signal transduction
ER signalling exists in two forms; genomic signalling, and non-genomic signalling.
The ligand-dependent genomic signalling in which 17β-estradiol binds to its
receptor, ER, is considered a pragmatic example of steroid hormone interac-
tion, with its mechanism shared by a number of other steroid hormones. 17β-
estradiol binds to ER in the cytosol, inducing migration to the nucleus. The
receptor then dissociates from the chaperones, causing dimerisation of the re-
ceptor, which thus activates the receptor transcriptional domain (Gruber et
al., 2002; Pearce et al., 2004; Deroo and Korach, 2006; Hall et al., 2001). The
dimerised ER then goes on to bind DNA either through sequences known as oe-
strogen response elements (specific, inverted, palindromic sequences) (Klinge,
2001), or via protein-protein interactions with other DNA binding transcription
factors (Li et al., 2001; Safe, 2001; Stossi et al., 2006). Both instances activate
7
transcription of ER dependent genes through coactivators and basal transcrip-
tion machinery (Glass et al. 2000; Smith et al., 2004; Kato et al., 2005).
Non-genomic signalling involves membrane localised ER, approximately
5-10% of all cellular ERs (Levin, 2009). When 17β-estradiol binds membrane
localised ER, various growth and proliferation signalling pathways can be acti-
vated. These are classified into four main signalling cascades: Ras/Raf/MEK/ERK
(Dos Santos et al., 2002; Tanaka et al., 2003; Woo et al., 2005), phosphatidyl in-
ositol 3 kinase (PI3K)/AKT (Castoria et al., 1999; Chambliss et al., 2005; Rus-
sell et al., 2000), phospholipase C (PLC)/protein kinase C (PKCs) (Incerpi et
al., 2003; Morley et al., 1992; Picotto et al., 1999), and cAMP/ protein kinase A
(PKA) (Farhart et al., 1996; Malyala et al., 2005). The activation of these path-
ways are cell-type specific, with the action of oestrogen bound ER depending on
a number of factors, leading to diverse responses.
1.1.3.2 Treatments of ER breast cancer
Surgery is the primary intervention method for breast cancer. However, pharma-
cological treatments exist to deprive ER breast cancers of oestrogen, and are
often prescribed in combination with surgery (36). Recent multi-gene assays
have improved patient treatment evaluation processes. Before these, prognosis
and benefit of chemotherapy was evaluated in patients through clinocopatho-
logical features: patient age, histological grade, tumour size, and location (20).
Multi-gene assays use the expression of tumour associated genes to estimate the
risk of cancer recurrence (21). Patients are then given a recurrence score, from
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which a treatment plan is determined (22). Adjuvant chemotherapy is generally
prescribed to tumours with a high risk of recurrence, and endocrine therapy to
those with a low risk of recurrence (22, 23).
Selective oestrogen receptor modulators (SERM) are competitive partial
agonists of ER (Cameron and Cameron, 2013). Their action is dictated by their
tissue environment, allowing them selective inhibition or stimulation of oestrogen-
like action (Riggs and Hartmann, 2003). Tamoxifen is one of the most effective
and commonly used SERM treatments (Howell et al., 2004). After its discovery
in 1967 (Jordan, 2006) it has been widely used, with it being the highest selling
hormonal breast cancer treatment drug in 2004 (Vose, 2004). It features in the
most current World Health Organization’s List of Essential Medicines (WHO,
2015).
Selective oestrogen receptor down regulators (SERD) bind directly to the
ER and cause degradation, and thus downregulation (Lee et al., 2017). Unlike
SERMs, SERDs do not possess agonist potential (Howell et al., 2004). The only
marketed SERD to date is fulvestrant (Di Leo et al., 2010). Fulvestrant is ad-
ministered via monthly injections, meaning it can have poor systemic exposure
(van Kruchten et al., 2015). This along with the lack of oral bioavailability has
led to current development of new generation SERDs (Govek et al., 2015; Lai et
al., 2015; Garner et al., 2015; Weir et al., 2016).
Aromatase inhibitors (AI) act to block the aromatisation of androgens (an-
drostenedione and testosterone) to oestrogen (Mauriac et al., 2003). By inhibit-
ing the activity of aromatase enzymes, the synthesis of oestrogen is blocked, and
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the transcription of oestrogen-responsive genes is downregulated (Huang et al.,
2002). Two forms of AI exist: irreversible steroidal inhibitors which cause a per-
manent, deactivating bond with aromatase enzymes(Brodie, 1982), and non-
steroidal inhibitors which form reversible bonds with aromatase enzymes (Mjar
et al., 1999).
1.2 Gene expression profiling
Gene-expression profiling has advanced our view of breast cancer and provided
a valuable tool for molecular diagnosis (Sotiriou and Pusztai, 2009). Gene ex-
pression profiles or ‘signatures’ may comprise of two to several thousand genes,
and provide prognostic or predictive information about the tumour being inves-
tigated (Dowsett and Dunbier, 2008). A study by Perou et al. (2000) compared
the gene expression profiles of 65 human breast cancers. These authors found
distinct molecular portraits of each tumour, and correlated gene expression that
reflected the biological features of the tumour. Proliferation clusters of genes
were also discovered by the authors in a manner that correlated with tumour
proliferation (Perou et al., 2000). Gene-expression profiling has also revealed in-
creased expression of genes associated with proliferation, such as Ki-67, MYBL2,
Survivin and STK, in ER+ tumours (Oh et al. 2006).
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1.2.1 Genome wide association studies of breast cancer
susceptibility
Recent advances in technology have allowed for the characterisation of mutated
genes that signify a cancer predisposition. Individuals displaying these mutated
genes are more likely to develop cancer than the general population (Garber and
Offit, 2005). BRCA1 and BRCA2, the APC gene, and the TP53 gene are ex-
amples of such genes. Genome wide association studies (GWAS) have emerged
in recent years as a method of identifying predisposition loci. GWAS examine a
genome-wide set of genetic variants across a number of individuals in order to
identify a genetic variant associated with a particular disease.
GWAS have associated single nucleotide polymorphisms (SNPs) near the
gene encoding ERα (ESR1 ) with an increased risk of breast cancer, revealing
a potential breast cancer susceptibility locus on chromosome 6q25.1 (Dunbier
et al., 2011; Fletcher et al., 2011; Zheng et al., 2009). Zheng et al. (2009) ini-
tially located a SNP, rs2046210, within the locus, upstream of the ESR1 gene,
which increased risk of breast cancer by an odds ratio of up to 1.59 in Chinese
women. The authors also showed a slightly weaker association in an indepen-
dent cohort of European women, implicating chromosome 6q25.1 as a suscep-
tibility locus (Zheng et al,. 2009). Further assessment of the susceptibility lo-
cus was undertaken by Stacey et al. (2010) who used a technique referred to as
ancestry-shift refinement mapping to show the association between rs2046210
and the pathogenic variant was not seen in European and African cohorts. They
did however, discover a SNP, rs9397435, that appeared to correlate with higher
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ESR1 expression and is associated with breast cancer risk in Asian, European
and African ancestry (Stacey et al., 2010). Another functional variant, rs6913578,
was found to be associated with breast cancer risk in Chinese, and European-
ancestry American women (Cai et al., 2011). It is suggested that the pathogen-
esis of these variants may be due to their genomic location, directly upstream of
the ESR1 gene (Cai et al., 2011).
1.2.2 Risk variants at chromosome 6q25.1
Subsequent analysis on chromosome 6q25.1 has further underscored the impor-
tance of the chromosome 6q25.1 locus on breast cancer susceptibility and pro-
gression. Using GWAS, two SNPs within the locus (rs10995194 and rs10034692)
have been significantly associated with mammographic density (a strong herita-
ble and intermediate phenotype of breast cancer) in Caucasian women (Brand
et al., 2015). When mammographic density was assessed in Asian women using
GWAS, three more SNPs within the chromosome 6q25.1 locus were found to be
significantly associated. These three SNPs had previously been found to be asso-
ciated with breast cancer risk or breast size (Mariapun et al., 2016).
A regulatory function has also been shown to correlate the chromosome
6q25.1 locus. In a GWAS of Chinese women, a SNP rs2046210 within the chro-
mosome 6q25.1 locus previously shown to be associated with breast cancer risk,
was shown to have a significant association with the expression levels of both
AKAP12 and ESR1 in adjacent normal breast tissues. Higher expression of both
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of the genes were shown to correlate to the AA AG genotype. This suggests the
association between chromosome 6q25.1 and breast cancer risk could be due to
SNPs regulating gene expression (Sun et al., 2016).
SNPs within chromosome 6q25.1 have also been implicated with breast
cancer risk for BRCA1 and BRCA2 mutation carriers. The analysis of four
SNPs within the locus showed independent associations with the risk of breast
cancer for BRCA1 mutation carriers with rs2046210, rs9397435, and rs999737.
rs9397435 and rs11249433 showed an association with risk of breast cancer for
BRCA2 mutation carriers (Antoniou et al., 2011).
The chromosome 6q25.1 locus has also been associated with multiple myeloma.
In a meta-analysis of European patients genotyping 600,000 SNPs, rs12374648
which lies within the chromosome 6q25.1 locus was shown to be associated with
multiple myeloma overall survival. This signifies a potential link with prognostic
information and the locus (Johnson et al., 2016).
1.2.3 Regulation effects of risk variants at chromosome
6q25.1
A recent study by Dunning et al. (2016) of 118,816 subjects analysing 3,872
common genetic variants across the chromosome 6q25.1 locus found five inde-
pendent causal variants, each having an effect on the risk of breast cancer in Eu-
ropeans. The findings also corroborated with the limited available data in Asian
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populations. Each of the variants, which lie upstream of ESR1, were shown via
reporter assays to regulate ESR1, with some additionally regulating CCDC170,
and RMND1. Four of the sites strongly associated with a risk of ER- tumours
were found to overlap enhancer regions, and act to decrease expression of ESR1,
RMND1, and CCDC170. The other causal variant found to increase risk of both
ER- and ER+ breast tumours overlaps a putative gene silencer, and acts to in-
crease expression of ESR1 and RMND1 (Dunning et al., 2016). These data also
suggest a cooperation between the genes within the chromosome 6q25.1 locus
leading to increased proliferation.
1.2.4 Co-expression with ESR1
A study by Dunbier et al. (2011) identified three open reading frames (ORFs)
that are tightly co-expressed with the ESR1 gene, corresponding with the breast
cancer susceptibility locus identified by Zheng et al. (2009), Stacey et al. (2010)
and Cai et al. (2011) at 6q25.1. Whilst investigating the factors associated with
the level of expression of ESR1, the previously uncharacterised ORFs C6ORF96
(now RMND1 ), C6ORF97 (now CCDC170 ), and C6ORF211 (nowARMT1 )
were found immediately upstream of the gene (Figure 1.1). The correlation be-
tween ESR1 and the ORFs was shown to be more likely due to co-expression,
not genomic alterations such as amplification (Dunbier et al., 2011).
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Figure 1.1: Location of the three genes co-expressed on chromosome
6q25.1. Location of the three genes RMND1, ARMT1, and CCDC170, with
respect to the ESR1 gene on chromosome 6 q25.1.
In order to gain a better understanding of their findings, Dunbier et al.
knocked down each ORF individually in an ER+ cell line MCF-7 using siRNA
techniques. The results showed a decrease in cell number in all samples com-
pared to the control, with the largest reduction in cell number occurring in the
C6ORF211 knockdown. These results corroborate the finding that ARMT1
correlates significantly with a proliferation metagene, suggesting that ARMT1
plays a significant role in the proliferation of ER+ breast tumours (Dunbier et
al., 2011). These data suggest the genes within this locus work cooperatively in
ER+ breast cancer to cause the increased proliferation seen in these tumours.
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1.2.5 CCDC170
Little is known about the function of CCDC170 (coiled-coil domain-containing
protein 170). However, higher CCDC170 expression has been correlated with
ER negative tumours, high proliferative features, and poor clinical outcomes
(Yamamoto-Ibusuki et al., 2015). Recurrent rearrangements between ESR1 and
CCDC170 have also been elucidated. The ESR1-CCDC170 rearrangement is
enriched in the more aggressive luminal-B tumours, and was found in eight out
of 200 ER+ breast tumours screened. The fusion creates truncated CCDC170
proteins which were shown to increase cell motility and anchorage-independent
growth, reduce endocrine sensitivity and enhance xenograft tumour formation
(Veeraraghavan et al., (2014). Previous to this, CCDC170 was found to have a
negative correlation to proliferation in breast tumours and was a predictor for
the effects of the anti-oestrogen drug tamoxifen on disease-free survival (Dunbier
et al., 2011).
1.2.6 RMND1
RMND1 (required for meiotic nuclear division 1) has been reported to localise
to mitochondria, behave as an integral membrane protein, and be necessary for
mitochondrial translation (Janer et al., 2012). Mutations to RMND1 have been
shown to be associated with end stage renal failure, dilated cardiomyopathy,
deafness, neurological involvement due to mitochondrial disease (Gupta et al.,
2016), and infantile onset mitochondrial disease (Ng et al., 2016). Continuing
16
research into RMND1 has revealed that the clinical phenotypes and prognoses
associated with RMND1 mutations are heterogeneous (Ng et al., 2016).
1.2.7 ARMT1
To date, little is known about the function of ARMT1. It is known to be a mem-
ber of the UPF0364 protein family (function unknown) that is expressed mainly
in the cytoplasm and does not co-localize with ER (Dunbier et al., 2011; Perry
et al., 2015). A recently published paper by Perry et al. (2015) has shed some
light on ARMT1, characterising it as “acidic residue methyltransferase-1” (ARMT1 ),
an enzyme that specifically methylates glutamate side chains of proliferating cell
nuclear antigen (PCNA). ARMT1 expression was knocked down using shRNA
in MCF-7 and SK-Br-3 breast cancer cell lines and then exposed to the geno-
toxic stresses UV, adriamycin (doxorubicin), and methyl methanesulfonate, and
survival assessed. The results suggest ARMT1 plays differential roles in re-
sponse to DNA damage in the two investigated cell lines. Increased sensitivity
to the genotoxic stress agents was observed in the SK-Br-3 cells, while in con-
trast, the MCF-7 cells showed an increased resistance (Perry et al., 2015). This
does not correlate to the findings of Dunbier et al. (2011) that reported knock-
down of ARMT1 in cultured MCF-7 cells induces suppression of proliferation.
The conflicting results seen in the Perry et al. (2015) study raises many
questions surrounding ARMT1. It is impossible to conclude that ARMT1 knock-
down in MCF-7 cells causes an increased resistance to genotoxic stress without
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first characterising the cells that grow after exposure to the stress. For instance,
if a large number of the cells that are observed to be alive are in fact in cellu-
lar senescence, it would not be true that the knockdown had caused increased
resistance in the cell line, but that it had instead caused a change to the prolif-
eration profile. Furthermore, how the activity of the methyltransferase leads to
such a change in cell proliferation and survival is poorly understood. Whilst the
Perry et al. (2015) work suggests that ARMT1 is a carboxyl methyltransferase
that functions in the DNA damage response pathway, it does not explain how
this translates to the observed change in cell proliferation and survival.
1.2.7.1 Saccharomyces cerevisiae ortholog
The saccharomyces cerevisiae (S.cerevisiae) ortholog to ARMT1, YMR027W
(Perry et al., 2015), has been shown to be upregulated in response to methyl
methansulfonate (Gasch et al., 2001). When the gene is knocked out in S. ceriv-
isiae, increased DNA damage or decreased repair is seen (Alvaro et al., 2007).
The effect YMR027W of DNA damage is consistent with with previously re-
ported functions of the DUF89 protein family, of which the protein product
of YMR027W is a member. Many enzymes in the DUF89 family have been
reported to rid cells of unwanted or harmful metabolites in processes termed
’damage pre-emption’(Linster et al., 2013), ’house cleaning’(Galperin et al.,
2006), or ’directed flow’(Reaves et al., 2013).
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1.3 The hallmarks of cancer
The complexity of cancer was organised into six biological capabilities when
Hanahan and Weinberg released their review, Hallmarks of Cancer (2011). The
review postulates that these six biological capabilities shared by all cancers, are
responsible for transforming normal cells to malignant. The six traits comprise
of sustaining proliferative signalling, evading growth suppressors, resisting cell
death, enabling replicative immortality, inducing angiogenesis, and activating
invasion and metastasis (Hanahan and Weinberg, 2000). A decade later, they
proposed two more emerging hallmarks: deregulating cellular energetics, and
avoiding immune destruction (Hanahan and Weinberg, 2011). As the function
of ARMT1 is not yet fully understood, investigation into the effects of ARMT1
dysregulation of the hallmarks of cancer could help distinguish a function.
1.3.1 Enabling replicative immortality
In recent years, cellular senescence has been conceptually postulated to be a
protective barrier against neoplastic expansion. Its onset in cells can be trig-
gered by a number of proliferation-associated abnormalities including shorten-
ing of telomeres, high levels of oncogenic signalling, mitochondrial retrogression,
oxidative stress, and DNA damage (Collado and Serrano, 2005; Collado et al.,
2007; Hanahan and Weinberg, 2011). Along with apoptosis, cellular senescence
can act as a protective barrier by preventing the spread of any acquired damage
to the next generation (Collado and Serrano, 2005; Collado et al., 2007; Hana-
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han and Weinberg, 2011).
Unpublished investigations regarding the knock down of ARMT1 in MCF-
7 cells have been undertaken by the Dunbier laboratory. Stably transfected
ARMT1 shRNA knockdown MCF-7 cell clones were produced to assess the ef-
fect of the knockdown on cell morphology and survival. This analysis suggested
an association between ARMT1 and ER+ breast tumour proliferation that may
be due to a subset of ARMT1 reduced cells entering a senescent state and halt-
ing cell division and survival, suggesting ARMT1 could be responsible for the
avoidance of the senescent state. (A. Dunbier, personal communication).
1.3.1.1 Analysis of replicative immortality
Many methods exist to measure cellular senescence, most based around the first
identified marker of senescence, lysosomal senescence-associated β-galactosidase.
This marker is only functional at pH 6.0 in senescent cells, cleaving the chro-
mogenic substrate galactosidase from glycoproteins, causing a blue stain to de-
velop in the cells that can be detected via bright field or phase contrast mi-
croscopy (Dimri et al., 1995; Debacq-Chainiaux et al., 2009). By using sub-
strates that become fluorescent after cleavage, fluorescence-activated cell sorting
or high throughput screening can also be used for detection (Debacq-Chainiaux
et al., 2009).
As senescent cells are metabolically active, the senescence-associated secre-
tory phenotype can be evaluated by antibody arrays (Coppe et al., 2008; Copep
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et al., 2010). This secretome is regulated by transcription factors, and can in-
clude factors such as extracellular proteases, matrix components, growth fac-
tors, pro-inflammatory cytokines, and chemokines (Coppe et al., 2008). Due to
this, cellular senescence can in some cases act as a tumour suppressor, stopping
the growth of cells at risk of malignant transformation (Acosta and Gill, 2012;
Lleonart et al., 2009). Contrarily, the cytokines and growth factors expressed
can be pro-tumoural and pro-invasive by changing the microenviroment of the
tissue to promote migration and invasion (Copep et al., 2010).
1.3.2 Sustaining proliferation signalling and evading growth
suppressors
Sustaining chronic proliferation is arguably the most fundamental character-
istic of a neoplastic cell. This is achieved largely through the manipulation of
growth factors. Although control of mitogenic signalling in normal tissue is not
fully understood, a better understanding is had in cancer cells (Lemmon and
Schlessinger, 2010; Witch et al., 2010; Hynes and MacDonald, 2006). Sustained
proliferative signalling in cancer cells is achieved in a number of ways. Growth
factor ligands can be expressed by the cells themselves, or normal cells in the
surrounding tissue can be stimulated to supply the neoplastic cells with growth
factors (Cheng et al, 2008; Bhowmick et al., 2004). Hypersensitivity to these
signals can be founded by elevated levels of receptor proteins, or structural al-
terations to these receptors (Fedi et al., 1997). Components downstream of sig-
nalling pathways can be modified to allow for growth factor independence (Medema
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and Bos, 1993).
1.3.2.1 Analysis of sustained proliferation
Clonogenic formation assays allow for the assessment of a cells ability to prolif-
erate to a sufficient level as to form a colony, under external stress signals. The
assay is a useful measure of the long term effects from cell harming agents such
as irradiation and UV exposure. Cell colonies of more than 50 cells are usually
counted manually by eye, however automated systems such as the Oxford Op-
tronix exist. Clonal formation ability can differ between cell lines (Woolston and
Martin, 2011), due to cell architecture and conformation influencing responsive-
ness (Sheild et al., 2009; Storch et al., 2010).
Live-cell imaging techniques allow for the monitoring of cell proliferation in
real-time, however they are outperformed by endpoint techniques when conflu-
ence is high (Single et al., 2016). Fluorescent nuclear staining followed by digital
fluorescence microscopy allows for an automated endpoint measure of cell num-
bers.
Soft agar assays allow for the assessment of anchorage independent growth.
Normal cells require signals of proliferation and differentiation from the base-
ment membrane, undergoing apoptosis when detached; a process called anoikis
(Fukazawa et al., 2004). The assay grows cells in agar with a thicker layer of
agar beneath, disallowing adhesion to the culture plate wall. The investigation
is indicative of the cells tumour suppression signalling molecules, and is often
22
indicative of tumorigenicity in vivo. (Borowicz et al., 2014).
1.3.3 Activating invasion and metastasis
Metastatic growth of tumours accounts for 90% of human cancer deaths (Sporn,
1996). Cancer cell migration, the directed movement of cells without passing
through barriers, and invasion, the movement of cells through the destruction of
barriers, are incompletely understood. However, invasion and metastasis have
been explained as a series of steps termed the invasion-metastasis cascade (Tal-
madge and Fidler, 2010; Fidler, 2003). Spread of neoplastic disease requires the
cell programme named epithelial-mesenchymal transition (EMT), which allows
cells to acquire invasive and migratory capacity (Yilmaz et al., 2009). Normal
development processes such as gastrulation require EMT, as it represents the
fundamental aspect of a cells biological ability for differentiation (Yilmaz et al.,
2009; Keller, 2005). Neoplastic cells often present a partial or incomplete EMT
(Zheng et al., 2015), or invade without EMT signals (Fischer er al., 2015). Tu-
mour microenvironment has also been implicated as an important factor, as sig-
nals between the surrounding tissue and the tumour can induce metastasis (Ege-
blad et al, 2010; Joyce et al., 2009).
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1.3.3.1 Analysis of invasion and metastasis
The scratch assay is a popular and simple assay that tracks confluent monolayer
cells in a two-dimensional plane. After a scratch is made to confluent mono-
layer cells, migration of the cells on the edges of the wounds are tracked via
images captured by microscopy until the scratch is closed (Liang et al., 2007;,
Rodriguez et al. 2005; Gyorffy et al., 2015). The scratches can be made mechan-
ically or manually, and the images captured on a number of live-imaging devices
and associated software. Automatic monitoring of cell wound closure can be
achieved with electric cell-substrate impedance sensing (Gorshkova et al., 2008;
Lo et al., 1995). Scratch assays are well regarded as an appropriate measure of
the regeneration of epithelial cells (Liang et al., 2007).
Wound healing is categorised into two main mechanisms (Jacinto et al.,
2001). One mechanism requires acquired motility of border cells. The cells spread
collectively on a new surface, whilst maintaining the integrity of the epithelium
(Fenteany et al., 2000). The other mechanism named ’purse-string closure’ oc-
curs in smaller wounds. A continuous pluricellular actin belt is developed be-
tween the cells along the border of the wound, which is then contracted via
myosin motors, thus healing the wound (Kiehart, 1999; Tamada et al. 2007).
These two mechanisms can occur within the same wound (Bement et al. 1993).
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1.4 Aims of study
Thus far, very little is known about the role of ARMT1 in normal and cancer
cells. It has been shown to be co-expressed with ESR1, CCDC170, and RMND1,
and to be associated with cellular proliferation (Dunbier et al., 2014). Poten-
tially, it may function as an enzyme that specifically methylates glutamate side
chains of proliferating cell nuclear antigen in response to DNA damage, thus de-
creasing sensitivity to genotoxic stress in MCF-7 cells (Perry et al., 2015). As
these claims have not yet been independently replicated, this project set out to
investigate this.
This project also aimed to analyse some aspects of the hallmarks of cancer
(Hanahan and Weinberg, 2000). Analysis of these hallmarks has the potential to
uncover the role ARMT1 plays in tumourigenesis.
The co-expression of ARMT1 with ESR1 and the other genes at the chro-
mosome 6q25.1 locus, along with the reported linkage between ARMT1 and
proliferation, suggests an underlying shared expression mechanism between the
genes. This co-expression was examined within this project.
The main aim of this project was to analyse the phenotypic effects of knock-
ing down and over expressing ARMT1 in MCF-7 cells. Specifically, this project
aimed to:
• Investigate the effect of altered ARMT1 expression in MCF-7 cells in re-
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gards to replicative immortality, sustained proliferation and evasion of growth
suppressors, and invasion and migration
• Investigate the effect of genotoxic stress on MCF-7 cells with altered ARMT1
expression
• Further analyse the co-expression of ARMT1 with ESR1 and the other
genes within the chromosome 6 q25.1 locus, by investigating the effects of knock-
ing down and over expressing ARMT1 in MCF-7 cells
A better understanding of ARMT1 could lead to new targets for clinical
therapies, which may lead to better prognoses for patients. The current litera-







The protocols for reagents are listed in Appendix A.
5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) - Roche, Switzerland.
30% Acrylamide/Bis solution, Bio-Rad, USA.
Acetic acid - Fisher Scientific, UK.
alamarBlue R© - Thermo Fisher Scientific, USA.
Ammonium persulfate (APS) – Sigma-Aldrich, USA.
Anti-α-tubulin monoclonal mouse antibody - Sigma-Aldrich, USA.
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Anti-HA Tag, Clone DW2 Monoclonal antibody - Sigma-Aldrich, USA.
β -mercaptoethanol – Sigma-Aldrich, USA.
BCA Protein Assay Kit – Thermo Scientific, USA.
Bovine Serum Albumin (BSA) – NEB, USA.
Citric acid monohydrate - Merck, Germany.
Crystal violet powder - Sigma-Aldrich, USA.
di-Sodium hydrogen phosphate - Normapur, UK.
Dimethyl sulfoxide (DMSO) – Sigma-Aldrich, USA.
Doxorubicin hydrochloride 98.0-102.0% (HPLC) - Sigma-Aldrich, USA.
ELC Anti-rabbit IgG HRP - Amersham Biosciences, USA.
Ethylenediaminetetraacetic acid (EDTA) - Scharlau, Spain.
Ethanol (EtOH) – Lab Supplies, NZ.
Fetal bovine serum (FBS) – Invitrogen, USA.
Formaldehyde - Scharlau, Spain.
Glutaraldehyde - Sigma-Aldrich, USA.
Hoechst 33342 Dye - Sigma-Aldrich, USA.
HycloneTM Trypan Blue Stain – Thermo Fisher Scientific, USA.
Immubilon-P Transfer membrane - Millipore, USA.
Magnesium chloride-6-hydrate - Sigma-Aldrich, USA.
Methanol, analytical grade – Fisher Scientific, UK.
Michigan Cancer Foundation – 7 (MCF-7) cell line – American Type Culture
Collection,USA.
Milli-Q - EMD Millipore, USA.
Paraformaldehyde - VWR Chemnicals, NZ.
Phosphate Buffered Saline - Thermo Fisher Scientific, USA.
Potassium hexacyano-ferrate (II) trihydrate - Sigma-Aldrich, USA.
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Potassium hexacyano-ferrate (III) - Sigma-Aldrich, USA.
Precision Plus Protein All Blue Standard - Bio-rad, USA.
PrimeScriptTM RT reagent Kit (Perfect Real Time) – Takara Bio Inc., Japan.
Primetime standard qPCR assay ARMT1 Hs.PT.49a.3485748 – Integrated DNA
Technologies, Inc., USA.
Primetime standard qPCR assay CCDC170 Hs.PT.49a.509482 – Integrated
DNA Technologies, Inc., USA.
Primetime standard qPCR assay ESR1 Hs.PT.49a.746988 – Integrated DNA
Technologies, Inc., USA.
Primetime standard qPCR assay GREB1 Hs.PT.49a.26216464 – Integrated
DNA Technologies, Inc., USA.
Primetime standard qPCR assay FKBP15 Hs.PT.49a.2552313 – Integrated DNA
Technologies, Inc., USA.
Primetime standard qPCR assay TFF1 Hs.PT.49a.168461 – Integrated DNA
Technologies, Inc., USA.
Primetime standard qPCR assay PUM1 Hs.PT.49a.1997572 – Integrated DNA
Technologies, Inc., USA.
Primetime standard qPCR assay RMND1 Hs.PT.49a.4325065 - Integrated DNA
Technologies, Inc., USA.
Propan-2-ol (isopropanol)– VWR, UK.
Puromycin - InVivoGen, USA.
Quick RNA miniprep kit – Zymo Research, USA.
RMPI [+] 2-Glutamine media – Gibco by Life Technologies, USA.
Sodium Chloride (NaCl) - Scharlau, Spain.
Sodium dodecyl sulfate (SDS) - Sigma-Aldrich, USA.
Sodium phosphate - Merck, Germany.
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TaqMan R© Gene Expression Master Mix – Applied Biosystems, USA.
Tetramethlyethlyenediamine (TEMED) - Scharlau, Spain.
Thermal seal, Real-time PCR Optical plastic sheet – Interlab Ltd, NZ.
Trim milk powder - Pams, NZ.
Tris(hydroxymethyl)aminomethane (Tris), Ultra Pure – Invitrogen, USA.
Triton X-100 - Sigma-Aldrich, USA.
Trypan blue - Sigma-Aldrich, USA.
Trypsin/EDTA – Invitrogen, USA.
Tween-20 - Sigma-Aldrich, USA.
Superscript R© III Reverse transcriptase – Life Technologies, USA.
2.1.2 Equipment
0.6 mL microtubes - Axygen, USA.
1.5 mL microfuge tube – Eppendorf, Germany.
1.7 mL microfuge tube – SorensonTM BioScience, Inc. USA.
1.8 mL Nunc CryoTube vials - Thermo Scientific, USA.
10 mL serological pipettes - Greiner Bio-One, Germany.
1 5mL and 50 mL Falcon tubes – Greiner Bio-one, Switzerland.
25 mL serological pipettes - Greiner Bio-One, Germany.
6-well, 24-well and 96-well Cellstar cell culture plates – Greiner Bio-one, Switzer-
land.
25 cm2 Cellstar cell culture flasks – Greiner Bio-one, Switzerland.
96-well Assay Plate: Black Plate, Clear Bottom with Lid – Corning, USA.
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96 well Essen ImageLock Plate - Essen BioScience, USA.
200 µL PCR tubes - Abgene, USA.
384-well optical plate – Applied Biosystems, USA.
500 mL filter system - Corning, USA.
ABI Prism 7900 HT – Applied Biosystems, USA.
C1000TM ThermoCycler – Bio-rad, USA.
Corning R© 1L Filter System – Corning, USA.
Corning R© Cell Lifter – Corning, USA.
Cryo Vials – Nunc, Denmark.
Cytation 5 Cell Imaging Multimode Reader – BioTek, USA.
Epoch Microplate Reader – Biotech, China.
HeracellTM 150i CO2 Incubator – Thermo Fisher Scientific, USA.
IEC Centra-4 x Centrifuge – International Equipment Company, USA.
IncuCyte FLR - Essen BioScience, USA.
Li-Cor Odyssey R© Fc Imaging System - Biotech, China.
Milli-Q Ultrapure water purification system - Millipore, USA.
Mini-PROTEAN 3 gel tank - Bio-rad, USA.
Mini Trans-Blot cell system - Bio-rad, USA.
Mr. Frosty 5100 Cryo 1◦ C Freezing Container - Thermo Fisher Scientific, USA.
Nanodrop – Nanodrop Technologies, USA.
Olympus DP71 camera – Olympus, Japan.
Olympus IX7I microscope – Olympus, Japan.
Pasteur Pipettes - Hirschmann, Germany.
POLARstar OPTIMA Multidetection Microplate Reader – BMG LABTECH,
Germany.
Stratalinker R© UV Crosslinker - Stratagene, Canada.
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TC10 Automated Cell Counter - Bio-rad, USA.
TC10 counting slides - Bio-rad, USA.
Thermomixer Heat Block - Eppendorf, Germany.
Tissue culture hood - EMAIL, Australia.
Water bath - Senco, USA.
WoundMaker - Essen BioScience, USA.
2.1.3 Software
Fiji ImageJ - Schindelin et al. (2012).
Gen5TM Data Analysis Software - BioTek, USA
Image J - Wayne Rasband, National Institutes of Health, USA.
IncuCyte Confluence version 1.5 software - Essen BioScience, USA.
Li-Cor Odyssey R© Fc Imaging System FieldBriteTM XT software - Biotech,
China.
Microsoft Excel 2016 - Microsoft, USA.
Prism 6.0 – GraphPad Software, Inc, USA.
SDS 2.4 – Applied Biosystems, USA.
Wound Confluence v1.5. IncuCyte software - Essen BioScience, USA.
2.2 Protocols for reagents
Protocols for reagents are listed in Appendix A.
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2.3 Tissue culture
Cell culture was performed under sterile conditions in a Class II Tissue Cul-
ture Hood. All MCF-7 cells were cultured in complete growth medium, contain-
ing phenol-red free RPMI [+]2-Glutamine media supplemented with 10% fetal
bovine serum (FBS). Cells were incubated at 37◦ C in 5% CO2 in a humidified
incubator.
2.3.1 MCF-7 ARMT1 knockdown cells
Cells of the human breast cancer cell line MCF-7 were obtained from the Amer-
ican Type Culture Collection (ATCC). These were transfected with either a
GIPZ lentiviral control vector, or a GIPZ lentiviral plasmid, containing either
the shRNA V2LHS 235844 or V3LHS 341844 which target the ARMT1 gene.
To maintain these cells, complete media contained puromycin at 0.02 µg/mL.
2.3.2 MCF-7 ARMT1 overexpression cells
Cells of the human breast cancer cell line MCF7 were obtained from the Amer-
ican Type Culture Collection (ATCC). These were transfected with either a
pDHA-neo control plasmid, or a pDHA-neo-ARMT1 plasmid. To maintain these
cells, complete media contained G418 at 1 µg/mL.
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2.3.3 Subculturing of cells
Medium was removed from the flask and replaced with phosphate buffered saline
(PBS) pre-warmed in a 37◦ C water bath. After this was removed, the cells were
incubated at 37◦ C in 5% CO2 in the humidified incubator with pre-warmed
0.05% Trypsin until adherent cells had detached from flask (approximately 5-7
minutes). In order to inactivate the Trypsin, pre-warmed complete medium was
added, and the cell mixture transferred to a 15 mL centrifuge tube. This was
centrifuged for 5 minutes at 500 rpm in the IEC Centra-4 x Centrifuge 5415R.
The supernatant was removed before the cells were resuspended in fresh, pre-
warmed complete medium. For passaging of cells, 10% of the resuspended cells
were transferred to a 25 cm2 cell culture flask containing complete medium.
2.3.4 Revival of frozen cells
Frozen cells were removed from the liquid nitrogen dewar and placed in the 37◦
C water bath. Once thawed, the cells were resuspended in 1 mL of pre-warmed
complete media before being centrifuged at 500 rpm for 5 minutes. The super-
natant was then removed and the cell pellet resuspended in 4 mL of pre-warmed
complete media, before being transferred to a 25cm2 cell culture flask. Cells
were then incubated in a humidified incubator at 37◦ C in 5% CO2.
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2.3.5 Cryogenic preservation of cell lines
After subculturing of cells (2.2.3) was complete, the cells were centrifuged again.
The pellet was then resupended in 1 mL freezing medium consisting of phenol-
red free RPMI [+]2-Glutamine media supplemented with 20% FBS and 10%
dimethyl sulfoxide (DMSO). The suspension was then aliquoted into 1 mL cry-
ovials which was then placed into a 5100 Cryo 1◦ C Freezing Container which
was stored at -80◦ C for 24 hours. The 5100 Cryo 1◦ C freezing container con-
trols the cooling of cells to a rate of 1◦ C per minute, which preserves the viabil-
ity of the cells. The cooled cryovials were transferred to liquid nitrogen for long
term storage.
2.3.6 Cell counting
Cells in suspension were mixed with Trypan blue at a 1:1 ratio. A 10 µL aliquot
of the cell and Trypan blue mix was pipetted onto both sides of a TC10 count-
ing slide, and a count of live cells per mL produced by the TC10 automated cell
counter for each side. The two values were averaged, with the resulting value
being taken as the number of cells per mL of cell suspension.
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2.4 Screening for gene expression using Quantita-
tive Real-Time Polymerase Chain Reaction
The primers used in this study are listed in Table 2.1.
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Table 2.1: Primers used in this study.


































































2.4.1 Extraction of RNA
Clones were seeded in triplicate in a 6-well culture plate at 4x105 cells per well
and incubated at 37◦ C in 5% CO2 for 24 hours. RNA was extracted from the
samples using the Zymo Research Quick-RNATM MiniPrep Kit and accompa-
nying protocol. Adherent cells were lysed using the RNA Lysis Buffer, and re-
moved using a Costar R© Cell Lifter. To purify the RNA yeild, the optional In-
Column DNase 1 Treatment was performed. After completion of the protocol,
the Zymo-SpinTM IIICG Column was placed in a clean 1.5 mL Eppendorf tube,
and the RNA eluted in 35 µL of DNase/RNase Free Water. The samples were
then placed on ice.
2.4.2 Quantification of RNA
To measure the quantity and quality of the extracted RNA, the Nanodrop 1000
was used. The DNase/RNase free water used to elute the RNA was used as the
blank measurement. Following this, samples were stored at -80◦ C.
2.4.3 Sample and standard cDNA synthesis
The PrimeScriptTM RT Reagent Kit was used to synthesize cDNA from the ex-
tracted RNA. For each sample, 500 ng of RNA in 6.5 µL was added to 3.5 µL of
master mix (components in Table 2.2). For standards, 2000 ng of RNA in 5 µL
38
was added to 5 µL of master mix. For No RT control, 500 ng of RNA in 6.5 µL
was added to 3.5 µL of modified master mix, containing no PrimeScript RT En-
zyme Mix I. The PCR tubes were then centrifuged and placed in the C1000TM
Thermo Cycler, which incubated the tubes for 15 minutes at 37◦ C, then heated
the tubes to 87◦ C for 5 seconds. Samples were then kept at -80◦ C.
Table 2.2: Components of Master Mix for one cDNA synthesis reaction.














RNA 6.5 5 5
mQH2O - - 2
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2.4.4 qPCR
cDNA samples were diluted to 4.44ng/µL using mQH20, and pipetted in tripli-
cate into a MicroAmp R© Optical 384-Well Reaction Plate, along with TaqMan
Gene Expression Master Mix and PrimeTime R© qPCR Assay (sequences in Ta-
ble 2.1).
Standard curves were created using standard cDNA serially diluted to 100 ng,
20 ng, 2 ng, 0.2 ng, 0.02 ng and run in triplicate.
The plate was sealed with an Interlab Real Time PCR Thermal Seal, then cen-
trifuged at 2000rpm for two minutes. The ABI 7900HT sequence detection sys-
tem was then used to expose the plate to the cycles tabulated in Table 2.3.
Table 2.3: qPCR cycle temperatures and times.
Stage Temperature (◦ C) Time (minute:second) Number of cycles
1 50 2:00 1











qPCR results were tabulated using the SDS 2.4 programme. During the entire
qPCR experiment, the Minimum Information for Publication of Quantitative
Real-Time PCR Experiments (MIQE) guidelines were adhered to (Bustin et al.,
2009). This involved insuring the threshold line of the experiment was at the be-
ginning of the exponential growth phase of the PCR, to allow for correct cycle
threshold (Ct) value calculation. The Second Derivative Maximum for absolute
quantification (Rebrikov and Trofimov, 2006) was used by the ABI 7900HT soft-
ware to calculate the Ct values at the point at which the rate of change of fluo-
rescence is fastest, usually the point in the cycle where the sample fluorescence
can first be distinguished from the background fluorescence. The Ct values are
then interpreted as the intersection of the amplification curve and the threshold
value. Samples were tested in both technical and biological replicates. When the
Ct values of the technical replicates varied by a standard deviation greater than
0.5, and an outlier replicate could be identified, the replicate could be removed
as per manufacturer instructions (.
The relative RNA of each gene of interest was normalised to the geometric mean
of the housekeeping genes, PUM1 and FKBP15. These two reference genes
have been found to be constitutively and stably expressed in breast cancers,
and therefore represent good normalisation genes for this study (Drury et al.,
2009). The normalised RNA expression values and their standard error values
were plotted using PRISM 5.0, and analysed with a two way ANOVA.
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2.5 Protein expression analysis - SDS-PAGE gel
and western blotting
Protein expression analysis was used in order to check the expression of the
pDHA-neo-ARMT1 plasmid in over expression clones and associated controls.
This is made possible by the presence of a double HA tag in the pDHA-neo-
ARMT1 plasmid. The associated control plasmid used to create the over ex-
pression control clone did not contain a HA tag.
The antibodies used for this study are listed in Table 2.4.
























Media was removed from cells seeded at 3x105 in 6-well plates and washed with
PBS. 150 µL of RIPA lysis buffer was added and the plate left on ice for five
minutes. The plates were scraped with a Cell Lifter and the contents transferred
to an ice-cold microcentrifuge tube which was kept on ice for 20 minutes, and
vortexed every five minutes. The samples were then centrifuged at 10,000 rpm
for 10 minutes at 4◦ C. The supernatant was transferred to a fresh ice-cold mi-
crocentrifuge tube and stored at -80◦ C.
2.5.2 Protein quantification
Quantification of protein samples was performed using the Thermo Scientific
colourimetric BCA Protein Assay Kit according to the manufacturer instruc-
tions. A series of BSA standards was used to create a standard curve in order to
determine protein concentration.
2.5.2.1 Bovine serum albumin standard curve
BSA standards were prepared on ice from a 2 mg/mL Albumin Standard in-
cluded in the BCA Protein Assay Kit and diluted with RIPA buffer to 0, 25,
125, 250, 500, 750, 1000, 1500, and 2000 µg. The standards were plated in trip-




After plating of BSA standards, protein samples were thawed on ice, and plated
in triplicate with the BCA Working Reagent into a 96-well plate. The plate was
mixed thoroughly on a plate shaker for 30 seconds, then covered in tinfoil and
incubated at 30◦ C for 30 minutes. The plate was cooled to room temperature
and the absorbance measured at 562 nm on the Epoch Microplate Spectropho-
tometer plate reader. The data were analysed using the Gen5TM Data Analysis
Software and resulting values used in the equation generated by the BSA stan-
dard curve to determine the total protein concentration of the samples.
2.5.3 Gel electrophoresis
2.5.3.1 Preparation of samples
Samples were prepared to contain a total of 20 ng protein in 10µL using RIPA
buffer as the diluent. To each sample, 2µL of loading dye was added. The sam-
ples were centrifuged briefly before being heated at 99◦ C for 5 minutes. The




In order to separate the target proteins from the isolated total proteins, a 1 mm
thick, 10% SDS-PAGE gel was used. The gel constituted of 10% acrylamide,
0.33% Bis solution, 0.1% SDS (w/v), 0.375 M Tris-HCl pH 8.8, 0.1% ammonium
persulfate (APS) (w/v), and 0.05% TEMED in dH2O. The APS was made fresh
before use and was added along with the TEMED moments prior to pouring the
gel. To prevent the gel drying out during polymerisation, isopropanol was added
to the top of the gel. The gel was then left at room temperature for 20 minutes.
2.5.3.3 Stacking gel
Before separation, the isolated proteins were stacked in a 5% gel. This gel con-
stituted of 5% acrylamide, 0.17% Bis solution, 0.1% SDS (w/v), 0.125 M Tris
pH 6.8, 0.1% APS, and 0.125% TEMED in dH2O. The isopropanol was com-
pletely removed from the top of the separating gel. The APS and TEMED was
added moments before the stacking gel was pipetted carefully on top of the sep-
arating gel. A comb was inserted into the stacking gel, and the gel left at room
temperature for 20 minutes to polymerise.
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2.5.3.4 Electrophoresis
The gel was placed in a Mini-PROTEAN 3 gel tank and submerged in 1 x SDS
running buffer. The samples were loaded into the gel along with 9 µL of Preci-
sion Plus Protein All Blue Standard used as a size marker in the SDS-PAGE gel
and western blot. The gel was run at a constant voltage of 100 V for 120 min-
utes until the dye had run off the gel.
2.5.4 Electrotransfer
The proteins were transferred onto a nitrocellulose membrane using the wet
transfer method. The nitrocellulose membrane was activated in methanol, be-
fore being placed along with the gel into a cassette with a layer of filter paper
and and two foam pads on either side. The cassette was then placed into a Mini
Trans-Blot cell system containing a transfer buffer ice pack, and the cassette
submerged in ice cold transfer buffer. The transfer was run at 90 V for 90 min-
utes.
2.5.5 Antibody binding
The membrane was blocked in TBST with 5% skim milk powder for one hour
on a shaker at room temperature. The membrane was transferred into a 50 mL
Falcon tube and incubated with the desired primary antibody overnight on a
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rotator at 4◦ C. The membrane was then washed three times for 10 minutes in
TBST on a shaker, before being incubated for one hour at room temperature
with the desired secondary antibody. TBST was then used to wash the mem-
brane five times for five minutes, before being poured off completely. A freshly
prepared PierceTM enhanced chemiluminescence (ECL) solution was poured over
the membrane which was left to develop for five minutes.
Following protein of interest imaging, the membrane was exposed to the an-
tibody for the housekeeping protein tubulin, in order to verify equal loading
between samples. The membrane was washed three times for five minutes in
TBS-Tween on a shaker. It was then placed in a fresh 50 mL Falcon tube and
incubated with the tubulin 1◦ primary antibody overnight on a rotator at 4◦ C.
The membrane was then washed three times for 10 minutes in TBS-Tween on a
shaker, before being incubated for one hour at room temperature with the de-
sired secondary antibody. TBS-Tween was then used to wash the membrane five
times for five minutes, before being poured off completely.
2.5.6 Chemiluminescent imaging
Freshly prepared PierceTM enhanced chemiluminescence (ECL) solution, diluted
1:40, was poured over the membrane and left to develop for five minutes. The
ECL developing solution was removed from the membrane before it was placed
in the Li-Cor Odyssey R© Fc Imaging System and exposed to the 700 nm and
chemiluminescence channels. The resulting image was used to determine the size
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of the protein of interest comparing it to the Precision Plus Protein All Blue
Standard size marker.
2.5.7 Densitometry
In cases where the loading control tubulin showed unequal loading, the density
of each of the control protein bands and the target protein bands were measured
using the Li-Cor Odyssey R© Fc Imaging Systems associated FieldBriteTM XT
software. The control protein bands were normalised to the strongest band, and
the resulting adjusted protein expression values used to calculate relative protein
concentration in each of the corresponding protein of interest bands.
2.6 Growth rate and doubling time analysis
The IncuCyte live-cell imaging system was used in order to assess cell prolifera-
tion of clones. It allows automated monitoring of cell proliferation based on con-
fluence (area metrics), by confluence measures and morphological phase-contrast
imaging, within the environment of a cell culture incubator. Cell proliferation is
measured by algorithms of monolayer confluence, then quantified by generation
of the linear relationship of cell number and confluence.
Cells were seeded in quintuplicate at 2x10 4 cells in 100µL of complete media
per well in 96-well culture plates. The plates were then incubated at 37◦ C in
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5% CO2 in the IncuCyte live-cell imaging apparatus for 72 hours where 25 phase-
contrast images at 4x were acquired every one and a half hours for 72 hours.
The resulting IncyCute data was graphed showing confluence over time, from
which the exponential growth phase of the cells could be identified. The conflu-
ence values of this phase were then used with the following equation in order to
identify the doubling time of the cells.
=
((72xLOG(2))
(LOG(final value)− LOG(initial value)))
2.7 Detection of senescence-associated β-galactosidase
activity
In order to detect senescence-associated β-galactosidase activity, the chromogenic
protocol described by Debaq-Chainiaux et al. (2009) was followed. Cells were
seeded at 5x104 cells per well into 6-well culture plates and incubated at 37◦ C
in 5% CO2 for 72 hours. The media was removed from the cells before they were
washed twice with PBS. The cells were then incubated for 5 minutes at room
temperature with 2 mL of β-galactosidase fixation solution. The cells were again
washed twice with PBS before 2 mL of β-galactosidase staining solution was
added to each well. The plates were then incubated at 37◦ C for 12-16 hours.
Following this the stain was removed, and the cells washed with PBS twice. To
dehydrate the cells, 1 mL of methanol was added to the cells and allowed to air
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dry.
Once dry, the cells were viewed and photographed using the Olympus DP71
camera. The images were then analysed using the Fiji ImageJ software.
2.7.1 Stressing of cells for the detection of senescence-associated
β-galactosidase activity
Three methods were used in order to stress cells for the detection of senescence-
associated β-galactosidase activity. Prior to treatment, cells were seeded at 5x104
cells per well and incubated at 37◦ C in 5% CO2 for 24 hours. Cells were then
treated with either 500 mM doxorubicin for 4 hours, 30% w/w 110 vol H2O2 for
24 hours, or media was removed and replaced with media lacking fetal bovine
serum for 48 hours. 72 hours post seeding and 48 hours post the initiation of
treatment, the above mentioned detection of senescence-associated β-galactosidase
activity method was followed (2.6).
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2.8 Analysis of DNA damage repair
2.8.1 Clonogenic assay
Cell density was optimised for clonogenic assays in order to ensure that after
10 days of growth in an incubator at 37◦ C in 5% CO2, untreated wells were
not over confluent causing colonies to join together. Cells were seeded in tripli-
cate at cell densities of 500, 1000, 1500, and 2000 cells per well in a 6-well plate.
Following optimisation, a cell density of 500 cells per well was chosen for future
clonogenic assays.
Cells were seeded in triplicate at 500 cells per well in 6-well plates and incu-
bated at 37◦ C in 5% CO2 for 24 hours. DNA damage was induced in cells by
exposing them to either Ultraviolet A at 254 nm or doxorubicin hydrochloride.
For assays treated with Doxorubicin hydrochloride, media was aspirated off cells
and in triplicates of each clone, replaced with media containing Doxorubicin hy-
drochloride at concentrations of 0, 100, 200, 300, 400, or 500 nM, before being
returned to an incubator at 37◦ C in 5% CO2 for four hours. Treated media was
then aspirated off and wells washed with 1 mL PBS, before 2.5 mL normal me-
dia added.
For assays treated with Ultraviolet A, plates were transferred to the Stratalinker R©
UV Crosslinker before triplicates of each clone were exposed to UV intensities of
0, 5, 10, 15, 20, or 25 J.m−1, before being returned to an incubator at 37◦ C in
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5% CO2.
Following treatment, both Ultraviolet A and doxorubicin, plates were incubated
at 37◦ C in 5% CO2 for 10 days, with media changes every 4 days.
For staining, media was aspirated off cells and 1 mL clonogenic fix (Appendix
A) carefully added to each well before plates were left for 15 minutes at room
temperature. Clonogenic fix was then aspirated off wells and 1 mL crystal vi-
olet stain (Appendix A) added before plates were left for a further 30 minutes
at room temperature. Plates were then slowly immersed in water and gently
agitated in order to remove stain without lifting colonies. Plates were then left
upside down and allowed to dry. Colonies greater than 30 cells were then scored
and counted manually.
2.8.2 Cytation cell growth assay
Cells were seeded in triplicate at 2000 cells per well in 96-well plates and incu-
bated at 37◦ C in 5% CO2 for 24 hours. DNA damage was induced in cells by
exposing them to either Ultraviolet A at 254 nm or Doxorubicin hydrochloride.
For assays treated with Ultraviolet A, plates were transferred to the Stratalinker R©
UV Crosslinker before triplicates of each clone were exposed to UV intensities of
0, 5, 10, 15, 20, or 25 J.m−1, before being returned to an incubator at 37◦ C in
5% CO2.
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For assays treated with doxorubicin hydrochloride, media was aspirated off cells
and in triplicates of each clone, replaced with media containing doxorubicin hy-
drochloride at concentrations of 0, 100, 200, 300, 400, or 500 nM, before being
returned to an incubator at 37◦ C in 5% CO2 for four hours. Treated media was
then aspirated off and wells washed with 100 µL PBS, before 100 µL normal
media was added.
Both Ultraviolet A and doxorubicin hydrochloride assays were incubated at 37◦
C in 5% CO2 for 72 hours before staining and fixing.
For staining and fixing, cells were exposed to 1 µg Hoechst 33342 and 0.25%
PFA for one hour on a plate shaker to stain cell nuclear material. Plates were
then fluorescently imaged on the Cytation Cell Imaging Multimode Reader,
which calculated cell number from six fields at 4x magnification.
2.8.3 Analysis of IC50
Data from clonogenic and cytation cell growth assays were transformed using
Prism 6.0 GraphPad Software to produce IC50 curves and associated P values.
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2.9 Analysis of cell migration
2.9.1 Cell wounding assay
Cell wounding assay was performed using the IncuCyte 2011A FLR, Essen im-
ageLock plates, and the 96 PTEE pin Wound-Maker to ensure wounds are au-
tomatically located by the IncuCyte software and analysed using wound conflu-
ence metrics.
Cell density optimisation was undertaken to ensure 100% confluence of cells 24
hours post seeding. Cells were seeded in quadruplicate at cell densities of 5000,
10000, 20000, 30000, 40000, and 50000 cells per well in a 96-well plate and incu-
bated at 37◦ C in 5% CO2 for 24 hours. Wells were inspected under a 10x objec-
tive microscope and confluence observed. A cell density of 50000 cells per well
was chosen for future experiments.
Cell clones were seeded at 50000 cells per well in quintuplicate in 96 well Essen
ImageLock Plates. Plates were incubated at 37◦ C in 5% CO2 for 24 hours to
ensure 100% confluence in each well. Precise wounds were then generated by
the 96 PTEE pin Wound-Maker on the monolayer of cells. Media was aspirated
from the wells before the cells were washed gently with pre warmed PBS, af-
ter which fresh pre warmed complete media was replaced. Cells were then in-
cubated at 37◦ C in 5% CO2 where images were acquired every 1 hour for 48
hours. To quantitatively measure wound closing, confluence was graphed using
the IncuCyte software, Wound Concluence 1.5.
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2.9.2 Soft agar anchorage independence assay
A 0.5% agarose base layer was prepared in 6-well plates by diluting sterile agarose
in cell culture medium, then dispensing 2 mL of the solution per well. This was
allowed to set on a level surface in the tissue culture hood before being trans-
ferred to a fridge for two hours to ensure complete setting.
The 0.35% agarose soft layer was prepared by diluting sterile agarose in cell cul-
ture medium containing 2000 cells. This was carefully dispersed over the base
layer, so as to not disturb this layer. The plates were then gently agitated to en-
sure even distribution of agarose and cells, before being placed to set on a level
surface in the tissue culture hood. Once set, plates were incubated at 37◦ C in
5% CO2. Complete medium was added after 24 hours, then removed and re-
placed every 72 hours after.
For staining, 12 days post seeding, media was aspirated from wells. 1 mL of Soft
Agar assay stain (Appendix A) was dispensed into wells and left for one hour at
room temperature. Stain was then aspirated off and replaced with H2O for 20








Recent genome wide association studies (GWAS) have exposed a potential breast
cancer susceptibility locus on chromosome 6q25.1 (Dunbier et al., 2011; Fletcher
et al., 2011; Zheng et al., 2009). Mutations to this locus have been shown to be
correlated with breast cancer susceptibility and progression (Brand et al., 2015;
Cai et al., 2011; Mariapun et al., 2016; Stacey et al., 2010). The locus holds
three uncharacterised genes that are tightly co-expressed with the ESR1 gene:
56
RMND1, CCDC170 and ARMT1.
In order to study the function of the ARMT1 gene, five MCF-7 cell clones
stably expressing the human lentiviral plasmid GIPZ, containing shRNAs di-
rected against ARMT1 were created, along with three empty plasmid controls,
by a previous student (Mason, 2013). Three MCF-7 cell clones stably express-
ing pDHA-neo-ARMT1 plasmids were also created by a previous student, with
one empty vector control (Mason, 2013). In order to use these cell clones in this
study, a verification of their ARMT1 expression was needed.
To verify the knockdown effect of the GIPZ plasmid, qPCR was employed.
To confirm the overexpression effect of the pDNA-neo-ARMT1 plasmid, qPCR
and western blotting techniques were used, the latter being made possible due
the inclusion of an HA-tag in the pDNA-neo-ARMT1 plasmid.
Dunbier et al. (2011) reported a decrease in cell proliferation after ARMT1
was knocked down by siRNA in oestrogen deprived MCF-7 cells. Alteration of
growth rate after gene dysregulation can be indicative of growth factor regula-
tion by said gene, making this an important avenue of investigation.
3.2 Validation by qPCR
In order to ensure the validity of the ARMT1 knockdown and overexpression
clones used in this study, the experimental technique of real-time quantitative
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polymerase chain reaction (qPCR) was used. qPCR is an accepted method of
measuring copy number variable regions (D’haene et al., 2010). Here, TaqMan
copy number assays were used to quantify the ratio of the gene of interest (ARMT1 )
to housekeeper genes (FKBP15 and PUM1 ) using dual hybridisation primer
probes, as seen in Table 2.1. The assays are single tube assays that consist of
probes that anneal to specific sequences targeted by the primers. The probes
used harness fluorescence resonance energy transfer (FRET) technology, with a
fluorescent dye attached to one end and a quencher dye attached to the other
end. The proximity of the quencher dye to the reporter dye causes the signal to
be undetectable when the probe is intact. During the process of PCR, the Taq
polymerase cleaves the fluorescent dye from the probe, dissociating it from the
quencher dye, and allowing signal detection by a real-time qPCR instrument.
In this instance the ABI Prism 7900 HT by ThermoFisher was used. The ABI-
prism is then able to detect the relative amounts of template DNA present for
each gene specific primer probe present, based on the fluorescence of each probe
specific dye.
The expression levels from three biological replicates were normalised to the
geometric mean of the expression of the reference genes, FKBP15 and PUM1,
in corresponding samples. These two reference genes have been found to be con-
stitutively expressed in breast cancers, and therefore represent good models for
gene normalisation in this study (Drury et al., 2009). The constitutive expres-
sion of these two reference genes were confirmed in the cell line used in this ex-
periment prior to investigation beginning (Dunbier, personal communication).
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3.2.1 Standard curve primer efficiency
In order to test qPCR primer efficiency, standard curves were produced from
a serial dilution of template so as to examine the linearity of the assays over
a range of concentrations. This is an important step in relative quantification
qPCR methods as it indicates the proportion of target DNA doubled by the
primer during the exponential phase of the PCR reaction. According to the
manufacturer guidelines, an efficiency between 90 and 110% is generally con-
sidered acceptable; samples amplified under higher or lower efficiencies will have
affected Ct values which in turn affects accuracy. Five 10 fold dilutions ranging
from 100 ng to 0.01 ng of DNA from MCF-7 cells were used as reference cDNA.
The resultant Ct values were plotted against the log of the cDNA concentra-
tion, and the slope calculated. The efficiency of the primers was then calculated
through the following equation:
E = 10− 1
slope
− 1
Representative standard curves and primer efficiencies can be found in Ap-
pendix B.
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3.2.2 Results of ARMT1 knockdown validation
Real-time Quantitative Polymerase Chain Reaction (qPCR) was used to com-
pare the relative expression levels of the ARMT1 gene in the five MCF-7 ARMT1
knockdown clones (A22, G7, G9, I17 and J1) and three control clones (B8, K3,
and K9). ARMT1 gene expression was analysed in the clones and controls at in-
creasing passage values in order to test for continued knockdown of ARMT1 by
the targeted shRNAs over increasing passage numbers.
All MCF-7 ARMT1 knockdown cell clones showed a decreased expres-
sion compared to the control clones (Figure 3.1). When averaged, the ARMT1
knockdown clones show a significant 4.01 fold decrease in ARMT1 expression
at passage number 6 (P<0.0001), a significant 3.74 fold decrease in ARMT1 ex-
pression at passage number 10 (P<0.0001), a significant 2.23 fold decrease in
ARMT1 expression at passage number 21 (P<0.0002), and a significant 6.89
fold decrease in ARMT1 expression at passage number 30 (P<0.0002).
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Figure 3.1: Relative gene expression of ARMT1 in MCF-7 ARMT1
knockdown clones and controls at passage numbers 6 (A), 10 (B), 21
(C), and 30 (D). Each value represents the average of three replicates, with
error bars indicating the standard error of the mean. Values from each biolog-
ical replicate were normalised using the reference genes FKBP15 and PUM1.
Values were plotted with error bars representing standard error of the mean.
Differential expression between MCF-7 ARMT1 knockdown clones and controls
was analysed using an unpaired t-test. Expression values found to be statisti-
cally significant between the ARMT1 knockdown clones and control clones are
indicated on the graph with summarised P values: *<0.05, **<0.01, ***<0.001,
****<0.0001.
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The relative expression of ARMT1 remained similar over increasing passage
number in the clones and controls. However, control clone K9 showed a change
in ARMT1 expression. As this clone contains an empty GIPZ plasmid, it was
expected to maintain constant expression of ARMT1 that was higher than the
knockdown clones and similar to that of the other controls. Despite this, as pas-
sage number increased, the expression of ARMT1 in clone K9 decreased. This
can especially be seen in graphs C and D representing passage numbers 21 and
30.
As clone K9 unexpectedly showed decreased ARMT1 expression that was
dissimilar to the expression of the other control clones, it was deemed an inap-
propriate control clone for use in this study (discussed further Section 3.5.1).
Analysis was also performed excluding K9. When clone K9 is removed from
analysis, the MCF-7 ARMT1 knockdown clones show a significant 4.62 fold de-
crease in ARMT1 expression at passage number 6 (P<0.0001), a significant 4.30
fold decrease in ARMT1 expression at passage number 10 (P<0.0001), a signifi-
cant 3.22 fold decrease in ARMT1 expression at passage number 21 (P<0.0001),
and a significant 9.77 fold decrease in ARMT1 expression at passage number 30
(P<0.0001).
The expression of ARMT1 in each of the MCF-7 ARMT1 knockdown clones
was statistically significantly lower than the expression of ARMT1 in the control
clones B8 and K3 across all of the examined passage values.
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3.2.3 Results of ARMT1 overexpression validation
Real-time Quantitative Polymerase Chain Reaction (qPCR) was used to com-
pare the relative expression levels of the ARMT1 gene in the three MCF-7 ARMT1
overexpression clones and control. ARMT1 gene expression was analysed in the
clones and control at increasing passage values in order to test for continued
overexpression of ARMT1 over increasing passage numbers.
The relative expression of ARMT1 remained similar over increasing pas-
sage number in all clones examined (Figure 3.2). Clones 20, 18 and 13 repre-
sent MCF-7 ARMT1 overexpression clones, and HA-3 their control. When av-
eraged, the ARMT1 overexpression clones show a significant 2.92 fold increase
in ARMT1 expression (P<0.05) at passage number 4, a 0.56 fold increase in
ARMT1 expression (P>0.06 ,not significant)at passage number 8, and a 1.125
fold increase in ARMT1 expression (P>0.09 ,not significant) at passage number
12.
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Figure 3.2: Relative expression of ARMT1 in MCF-7 ARMT1 over-
expression clones and controls at passage numbers 4 (A), 8 (B), and
12 (C). Each value represents the average of three biological replicates, with
error bars indicating standard error of the mean. Values from each biological
replicate were normalised using the reference genes FKBP15 and PUM1. Values
were plotted with error bars representing standard error of the mean. Differen-
tial expression between MCF-7 ARMT1 ovexpression clones and controls was
analysed using an unpaired t-test. Expression values found to be statistically
significant between the ARMT1 overexpression clones and control clones are
indicated on the graph with summarised P values: *<0.05, **<0.01, ***<0.001,
****<0.0001.
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The overexpression clones were expected to maintain constant expression of
ARMT1 that was higher than the control. However, the expression of ARMT1
in clone 18 was consistently lower than clones 20 and 13, suggesting clone 18 is
not expressing as much ARMT1 as the other clones, 20 and 13. This is most
clearly evident in graph C passage number 12.
As clone 18 does not represent an example of ARMT1 overexpression, is
removed from analysis (discussed further Section 3.5.2). When clone 18 is re-
moved from analysis, the ARMT1 overexpression clones show a significant 3.81
fold increase in ARMT1 expression (P<0.01) at passage number 4, a significant
1.70 fold increase in ARMT1 expression (P<0.05) at passage number 8, and a
significant 1.69 fold increase in ARMT1 expression (P<0.01) at passage number
12.
The expression of ARMT1 in the overexpression clones 20 and 13 was sta-
tistically significantly higher than the expression of ARMT1 in the control clone
across all of the examined passage values.
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3.3 Validation of overexpression by western blot-
ting
To ensure the pDNA-neo-ARMT1 plasmid was being expressed in the ARMT1
overexpression clones, analysis of protein samples using SDS-PAGE and western
blot with an antibody against the HA tag contained in the plasmid was per-
formed. Analysis of the protein samples through SDS-PAGE and western blot
analysis can be seen in Figure 3.3. Strong HA-tagged bands can be seen in sam-
ples 20 and 13, however as the tubulin loading control showed unequal protein
amounts between the four samples, the protein bands were examined using den-
sitometric analysis.
Figure 3.3: Western blot showing HA-tagged proteins. Representative
western blot showing HA-tagged proteins and tubulin loading control. Subse-
quent blots can be found in Appendix C. 20 ng of extracted protein from each
clone was separated on SDS-PAGE and transferred to a nitrocellulose mem-
brane, then incubated with antibodies to detect HA-tag then tubulin.
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The western blot was imaged using the Li-Cor Odyssey R© Fc Imaging Sys-
tem and analysed for intensity with the associated FieldBriteTM XT software,
producing a density value for each band after multiple exposures (Figure 3.4).
The tubulin protein density values from each sample were then normalised to
the strongest band, that of the HA-3 sample. The HA-tagged ARMT1 protein
density values were then adjusted according to the relative protein concentration
in each sample calculated by the normalisation of the tubulin band. Normalised
and centered values from three biological replicates can be seen in Figure 3.5.
Figure 3.4: Western blot showing HA-tagged proteins with quan-
tified bands. Representative western blot showing HA-tagged proteins and
tubulin loading control with quantified band strength. Subsequent blots can be
found in Appendix C. 20 ng of extracted protein from each clone was separated
on SDS-PAGE and transferred to a nitrocellulose membrane, then incubated
with antibodies to detect HA-tag then tubulin. To quantify protein expres-
sion, band intensity was measured using Li-Cor Odyssey R© Fc Imaging System
FieldBriteTM XT software and normalised to the HA-3 sample.
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Figure 3.5: Adjusted densitometry values of HA-tagged ARMT1 pro-
tein expression. HA-tagged ARMT1 protein densitometry readings were
adjusted according to the normalised tubulin values. Each bar represents the
average of three biological replicates, with error bars representing the standard
error of the mean.
The adjusted HA-tagged ARMT1 protein expression shows a strong ex-
pression of the plasmid in overexpression samples 20 and 13 (0.1697 and 0.4592
signal units respectively), however only a weak expression of the plasmid can be
seen in sample 18 (0.0459 signal units). The control clone HA-3 displayed very
little expression (0.002 signal units).
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3.4 Assessment of cell proliferation
In order to analyse the growth characteristics of the clones in real time, the In-
cuCyte automated digital live imaging system was employed. No significant dif-
ferences were seen in the doubling time of each of the MCF-7 ARMT1 knock-
down clones and controls (Figure 3.6). Likewise, the MCF-7 overexpression
clones and control all showed similar doubling times. The average doubling time
of the MCF-7 ARMT1 knockdown clones and controls was not significantly dif-
ferent as the average doubling times equated to 25.14 hours and 26.41 hours re-
spectively (Figure 3.6 A). The greatest variation was seen in the control clones,
as clone B8 had the longest doubling time of all clones at 29.94 hours, and clone
K3 had the shortest doubling time of all clones at 22.97 hours. The variation
between doubling times of the MCF-7 ARMT1 knockdown clones was minimal,
with the longest doubling time being 25.95 hours, and the shortest doubling
time being 23.60 hours.
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Figure 3.6: Doubling time of cell clones extrapolated from IncuCyte
growth curve. Each value represents the average of 18 replicates collected
from three biological replicates, with error bars displaying the standard error
of the mean. Doubling time was calculated from the exponential growth phase
identified from the IncuCyte growth curve using the equation in Section 2.5.
Difference in growth rate between MCF-7 ARMT1 knockdown and overexpres-
sion clones and respective controls were analysed using an unpaired t-test.
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Similarly, little difference in doubling time was seen between the MCF-7
overexpression clones and controls. The two MCF-7 ARMT1 overexpression
clones had similar doubling times of 29.80 hours and 27.49 hours, the average
of which being 28.65 hours. This was not significantly different to the doubling
time of the control clone at 27.03 hours (Figure 3.6 B).
3.5 Discussion
3.5.1 MCF-7 ARMT1 knockdown clones
In order to investigate the function of ARMT1, MCF-7 cell clones with ARMT1
knockdown by stably transfected shRNA, and MCF-7 cell clones with ARMT1
over expression by stable transfection with pDHA-neo-ARMT1, had been pre-
viously generated in the Dunbier laboratory. In order to use these clones for in-
vestigations within this study, the knockdown and overexpression of ARMT1 in
these clones needed to be verified. In order to analyse the expression of ARMT1
in the clones, two techniques, qPCR and western blotting, were employed.
When the MCF-7 ARMT1 knockdown clones and controls were subjected
to qPCR analysis, a trend of ARMT1 knockdown was seen in the knockdown
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clones when compared to the controls. At each of the explored passage values,
each ARMT1 knockdown clone showed a decrease in expression compared to the
controls. This knockdown was maintained over the increased passage numbers,
suggesting increasing passage number of the cells does not alter the effectiveness
of the shRNAs targeting ARMT1 in the clones. The knockdown of the MCF-7
ARMT1 knockdown clones was significant when compared to the controls, and
therefore represent a good model of ARMT1 knockdown in MCF-7 cells to be
used in this study.
The only MCF-7 ARMT1 knockdown clone to show an unexpected trend
was control clone K9. This clone showed a decrease in ARMT1 expression as
passage number increased. The expression of ARMT1 in this clone was much
lower than the expression of the other control clones at passage numbers 21 and
30. This decrease in expression could be due to a contamination of the K9 cells
with one of the ARMT1 knockdown cells, however, as original frozen stocks of
K9 were used throughout this study, it is unlikely. Previous work has shown the
chromosome 6q25.1 locus is often epigenetically modified (White, 2013). It is
possible that epigenetic mutations occurred to the ARMT1 gene in clone K9,
reducing its expression.
Although the cumulative knockdown of the MCF-7 ARMT1 knockdown
clones was significant when compared to the cumulative expression of the con-
trol clones, it is more significant when clone K9 was removed from analysis. As
clone K9 showed an unexpected trend of decreased ARMT1 expression that was
dissimilar to the expression of the other control clones, it was deemed an inap-
propriate control clone for use in this study, and was therefore removed from
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any future analysis.
3.5.2 MCF-7 ARMT1 overexpression clones
The MCF-7 ARMT1 overexpression clones and controls examined in this study
showed mixed results. Firstly, qPCR results showed similar expression of ARMT1
at each of the passage numbers examined, suggesting the plasmid incorporated
in the cells is stably expressed up to these passage numbers. Secondly, qPCR
also showed an increase in ARMT1 expression in clones 20 and 13 that was sig-
nificantly higher than the control, but not in clone 18.
The trend of these results was seen again when the MCF-7 ARMT1 over
expression clones and controls were examined by western blot. A strong HA-
tagged band was present in clones 20 and 13 with normalised signal units of
0.1697 and 0.4592 respectively, however only a weak band was present in clone
18, with a normalised signal unit of 0.0459. This evidence suggests the plas-
mid that is responsible for over expressing the ARMT1 gene is not being ex-
pressed as strongly in clone 18, as it is in clones 20 and 13. This could be due
to the promoter used in the pDHA-neo-ARMT1 plasmid becoming silenced. Al-
though CMV is an accepted and widely used promoter in MCF-7 cells (Mitkim
et al., 2015; Thompsom et al., 2011), it has also been previously shown to ex-
hibit variability in the expression of the target genes (Furth et al., 1994). The
most common reason for CMV promoter silencing is due to hypermethylation
of the promoter (Brooks et al., 2004), or over stimulation by cAMP or protein
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kinase C-dependent pathways (Bauer et al., 2005).
When considering the expression of ARMT1 in the MCF-7 ARMT1 over-
expression clones, the findings of the western blot analysis coincide with those of
the qPCR results. When clone 18 is removed from analysis, a clear overexpres-
sion of ARMT1 is seen in the MCF-7 ARMT1 clones compared to their con-
trols. For this reason, clone 18 was not used in any further experiments in this
study, and clones 20 and 13 were considered to be a good model for ARMT1
overexpression when compared to the control.
For future studies, investigations into the expression of ARMT1 in the
clones could be further examined by western blot analysis of ARMT1 itself,
without the HA tag. This would provide another quantitative measure of the
expression of ARMT1, and also allow for the assurance that the mRNA encod-
ing ARMT1 was being fully transcribed into the ARMT1 protein. This method
of expression exploration was not able to be undertaken in this study due to the
unavailability of a reliable anti-ARMT1 antibody, however it could be a useful
tool for future investigations into ARMT1 expression.
The results of this study have yielded a set of clones that will represent
ARMT1 overexpression in MCF-7 cells, and a set of clones that will represent
ARMT1 knockdown in MCF-7 cells. These sets of clones, excluding those men-
tioned previously will be used in further investigations within this study.
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3.5.3 Cell proliferation rate
Assessment of cellular proliferation rate in gene expression manipulated cells is
an important step in assessing the function of a gene. This study examined the
rate of cellular proliferation in the MCF-7 ARMT1 knockdown and overexpres-
sion clones, along with their respective controls. Although the study showed mi-
nor variation between the clones, no statistically significant difference was seen
between the two groups and their clones, nor was any trend evident in the two
groups.
The American Type Culture Collection (ATCC) reports the average dou-
bling time of MCF-7 cells to be 29 hours (ATCC, 2017). This is consistent with
the results of this study, in which the average doubling time of all MCF-7 clones
examined was shown to be 26.21 hours. This small difference in reported dou-
bling time could be due to differences in the method of doubling time calcula-
tion. This study utilised the IncuCyte live imaging system in order to calculate
the the growth rate of the cells. This is a confluence based method, by which
growth rate is calculated via changes to well confluence, not actual cell number.
It has been shown that a more accurate method of calculating cell number in
monolayer cells comes from using both a real-time system such as the IncuCyte,
and an endpoint assay. This was shown as a more effective way of evaluating
monolayer cells in culture (Single et al., 2015).
Dunbier et al. (2011) reported a decrease in cell proliferation after ARMT1
was knocked down by siRNA in oestrogen deprived MCF-7 cells. Contrarily, this
75
study did not show a difference in cell proliferation between MCF-7 ARMT1
knockdown and overexpression clones and their respective controls. However,
some methodological differences exist between the two studies. Firstly, cells were
oestrogen deprived when assessed in the Dunbier et al. (2011) paper. A further
growth rate examination of the clones used in this study under oestrogen de-
prived conditions could indicate a relationship between ARMT1 and cell prolif-
eration in oestrogen deprived conditions.
This discrepancy of results could again be due to the method of cell number
calculation. The method used by the Dunbier et al. (2011) study involved an
end-point cell counting assay after six days of growth. As discussed, this study
used a confluence based measurement of growth. The use of this in combina-
tion with an end-point assay would provide more accurate results (Single et al.,
2015), which may affect the perceived difference.
The differences between transient and stable clones could also be affect-
ing the results. The Dunbier et al. (2011) study examined cells that were tran-
siently transfected with siRNA knockdown, whereas this study used stably trans-
fected clones with shRNA knockdown. In transiently transfected cells, the knock-
down of the gene commences approximately 24 hours prior to cell examination
beginning. In stably transfected cells however, the knockdown of the gene could
have occured in the cells weeks or months prior to the examination beginning,
depending on the passage number of the cells. If the knockdown of the gene af-
fected an essential function of the cell, compensation via manipulation of an-
other pathway could have occured to combat the affected essential function.
This could be further examined by the use of inducible clones.
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The results of this study suggest the dysregulation of ARMT1 does not
affect the doubling time of MCF-7 cells. No statistically significant differences
were seen between either the ARMT1 knockdown cells and their controls, or the
ARMT1 overexpression cells and their controls. If this aspect of ARMT1 dys-
regulation was to be further examined however, utilising a method that involved
both real-time and end point examination could be beneficial, as a small differ-
ence was seen between the average doubling time of all MCF-7 clones examined
and the reported doubling time of MCF-7 cells.
3.6 Conclusion
Most of the MCF-7 cell clones used in this experiment showed both the ARMT1
expression levels expected of them, and that these expression levels did not change
over increasing passage numbers. The MCF-7 ARMT1 knockdown clones (A22,
G7, G9, and I17) and controls (B8 and K3) will provide a good model of ARMT1
knockdown for further investigation. The MCF-7 ARMT1 overexpression clones
(20 and 13) and control (HA-3) will provide a good model for ARMT1 overex-
pression for further investigation.
The results of this study indicate ARMT1 dysregulation does not cause
a difference to the proliferation rate of MCF-7 cells. Doubling time analysis of
the MCF-7 ARMT1 knockdown and overexpression clones showed no significant
difference when compared to the controls. The doubling time of the clones used





Investigation into the role of
ARMT1 in the hallmarks of cancer
4.1 Study rationale
The function of ARMT1 was assessed in this study through a variety of pheno-
typic assays. This involved exposing the MCF-7 ARMT1 knockdown and over-
expression clones and controls to a number of experimental techniques, aimed at
examining the hallmarks of cancer.
Previous research has shown an increase in the number of senescent cells
in a population of cells with reduced expression of ARMT1 (Mason, 2013). As
recent bodies of work have centred on exploiting senescence as a basis of can-
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cer therapy (Acosta et al., 2012), further investigation into the effect of reduced
ARMT1 expression and senescence was undertaken.
Cell invasion was assessed through migration. A commonly used method to
measure cellular migration is through cell wounding assays. Measuring the speed
of cell migration across a wound can be indicative of a cell’s ability to migrate
and invade (Simpson et al., 2008; Furtado et al., 2012).
Difference in anchorage independent growth can be indicative of the tu-
mourigenicity of the cancer. The ability of cells to both survive despite growth
suppressive signals, and proliferate without the positional signals of adhesion is
thought to be requirement in cancer progression (Fukazawa et al., 2004).
Perry et.al. (2015)characterised ARMT1 as Acidic Residue Methyltransferase-
1, thus naming the gene and suggesting the gene product capable of methylating
glutamate side chains of proliferating cell nuclear antigen in breast cancer cells.
In addition. increased survival was reported after the genotoxic stresses, UV and
doxorubicin, in MCF-7 ARMT1 knockdown cells compared to controls. From
this, these authors concluded ARMT1 plays a role in the DNA damage response
system, by way of post-translational modifications. This study has assessed the
validity of this claim through both clonogenic formation and cellular growth.
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4.2 Replicative immortality via cellular senescence
Analysis of cellular senescence in gene expression manipulated cancer cells can
be indicative of a relationship between the gene of interest and the replicative
ability of the tumour. In order to detect cells in a senescent state, a colourimet-
ric assay using β-galactosidase staining was employed. The stain distinguishes
senescent cells by way of the component X-gal, which is broken down into a vis-
ible blue precipitate by senescent cells at pH 6. The cell clones were examined
for senescence associated β-galactosidase activity under both normal conditions,
and stressed conditions. These stressed conditions included incubating the cells
in serum free media, treating the cells with hydrogen peroxide, and treating the
cells with doxorubicin.
4.2.1 Senescence associated β-galactosidase activity
The proportion of senescence associated β-galactosidase activity in each MCF-
7 ARMT1 knockdown clone and control were similar (Figure 4.1). Clones A22,
G7, I17, J1 (knockdown clones), and B1 (control clone) all showed a propor-
tion of stained cells that ranged between 18.07% and 20.00%. MCF-7 ARMT1
knockdown clone G9, and control clone K3 had a proportion of stained cells out-
side this range with 30.41% and 12.45% respectively.
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Figure 4.1: Percentage of cells showing senescence associated β-
galactosidase activity in MCF-7 ARMT1 knockdown clones and
controls. Cells were seeded at 5x104 cells per well into 6-well culture plates
and incubated for 72 hours before being stained. Each data point represents the
average of nine wells, taken from three biological replicates. Cell counts for each
well totalled at least 500 cells. Error bars represent the standard error of the
mean.
The mean proportion of stained cells from all MCF-7 ARMT1 knockdown
clones at 21.16% compared to the mean proportion of stained cells in the control
clones at 15.26% was not statistically significant (Figure 4.2).
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Figure 4.2: Average percentage of ARMT1 knockdown clones and
controls showing senescence associated β-galactosidase activity. Cells
were seeded at 5x104 cells per well into 6-well culture plates and incubated for
72 hours before being stained. Each data point represents the average senes-
cence associated β-galactosidase activity for ARMT1 knockdown clones and
control clones. Error bars represent the standard error of the mean. Differ-
ences in senescence associated β-galactosidase activity between MCF-7 ARMT1
knockdown clones and controls was analysed using an unpaired t-test.
4.2.2 Senescence associated β-galactosidase activity in stressed
cells
Little difference was seen in the proportion of stained cells when the MCF-7
ARMT1 knockdown clones and controls were exposed to stressing agents. MCF-
7 ARMT1 knockdown clones and controls grown in serum free media showed
a proportion of staining ranging from 8.60% in clone A22, to 30.32% in clone
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J1. The mean proportion of staining in all MCF-7 ARMT1 knockdown clones
was 16.65%, which when compared to the mean staining of the control clones at
18.80% was not statistically significant (Figure 4.3 A).
MCF-7 ARMT1 knockdown clones and controls treated with hydrogen per-
oxide showed a proportion of stained cells that ranged from 7.84% in clone K3
to 17.01% in clone G9. The mean proportion of staining in the MCF-7 ARMT1
knockdown clones and controls was 15.65% and 12.84% respectively. These dif-
ferences were not found to be statistically significant (Figure 4.3 B).
Lastly, MCF-7 ARMT1 knockdown clones and controls treated with dox-
orubin showed a mean proportion of stained cells ranging from 19.47% in clone
B8 to 39.48% in clone J1. 32.80% was the mean proportion of stained cells in
the MCF-7 ARMT1 knockdown clones, and 20.32% in the control clones. Again,
these values were found not to be statistically significantly different (Figure 4.3
C).
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Figure 4.3: Percentage of cells showing senescence associated β-
galactosidase activity in MCF-7 ARMT1 knockdown clones and
controls when treated with serum free media (A), hydrogen perox-
ide (B), and doxorubicin (C). Cells were seeded at 5x104 cells per well into
6-well culture plates and incubated for 72 hours before being stained. Each
data point represents the average of three wells, with cell counts for each well
totalling at least 500 cells. A: Cells incubated with serum free media. B: Cells
treated with 31.25 µg/mL hydrogen peroxide for four hours. C: Cells treated
with 100 nM doxorubicin for four hours. Difference in senescence associated β-
galactosidase activity between MCF-7 ARMT1 knockdown clones and controls
was analysed using an unpaired t-test.
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4.3 Cell invasion and metastasis
In order to evaluate the invasion and metastatic ability of the MCF-7 ARMT1
knockdown and overexpression clones, cell migration was assessed through wound
healing. Rate of wound healing is indicative of a cells ability to migrate and in-
vade.
4.3.1 Wound healing
No significant difference was seen between the MCF-7 ARMT1 knockdown clones
and controls when wound healing was assessed (Figure 4.4). The wound cre-
ated in the monolayer of cells was closed at a similar rate between the MCF-7
ARMT1 knockdown clones and their controls. This rate is quantified as wound
confluence (Figure 4.5). Although the average wound confluence of the MCF-
7 ARMT1 knockdown clones was higher than the control clones at each of the
time points examined, this small difference was not statistically significant.
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Figure 4.4: Images of MCF-7 knockdown clone and control wound
healing. Images were taken from the IncuCyte live imaging system. Wound
closing of one MCF-7 ARMT1 knockdown clone and respective control are
represented by images from one well of cells at examined time points.
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Figure 4.5: Wound confluence percentage of MCF-7 ARMT1 knock-
down clones and controls. Each bar represents the average of all MCF-7
ARMT1 knockdown clones or controls. Wound confluence was examined in each
clone 15 times over three biological replicates. Values were plotted with error
bars representing standard error of the mean. Difference in wound healing be-
tween MCF-7 ARMT1 knockdown clones and controls was analysed using an
unpaired t-test.
A change in the rate of wound healing was observed between the MCF-7
ARMT1 overexpression clones and control. Representative images from one well
of an ARMT1 overexpression clone and a control clone showed increased wound
healing in the ARMT1 overexpression clones compared to the control clone
(Figure 4.6). Similarly, when the wound confluences of all wells of all clones
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across all biological replicates are averaged, a statistically significant increase
in wound confluence is seen in the ARMT1 overexpression clones compared to
the control clone across all time points examined (Figure 4.7). At 24 hours post
scratch, the ARMT1 overexpression clones showed a significant 15.56% increase
in wound confluence compared to the control clone (P<0.0435). This difference
was increased to 24.19% (P<0.0085) and 25.638% (P<0.0073) at time points 48
hours and 72 hours post scratch, respectively. This suggests the overexpression
of ARMT1 in MCF-7 cells causes an increase in wound healing, and thus an in-
crease in the ability of the cells to invade.
Figure 4.6: Images of MCF-7 overexpression clone and control wound
healing. Images were taken from the IncuCyte live imaging system. Wound
closing of one MCF-7 ARMT1 overexpression clone and respective control are
represented by images from one well of cells at examined time points.
89
Figure 4.7: Wound confluence percentage of MCF-7 ARMT1 overex-
pression clones and controls. Each bar represents the average of all MCF-7
ARMT1 overexpression clones or controls. Wound confluence was examined in
each clone 15 times over three biological replicates. Values were plotted with
error bars representing standard error of the mean. Difference in wound healing
between MCF-7 ARMT1 knockdown clones and controls was analysed using an
unpaired t-test. Expression values found to be statistically significant between
the ARMT1 overexpression clones and control clones are indicated on the graph
with summarised P values: *<0.05, **<0.01, ***<0.001, ****<0.0001.
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4.4 Evading growth suppressors
4.4.1 Soft agar anchorage independent growth
Soft agar assays which examined the ability of the clones to avoid anoikis showed
little difference between the MCF-7 ARMT1 knockdown clones and controls.
The percentage of clonal formation in the ARMT1 knockdown samples was
slightly lower than the controls with 0.048% growth and 0.052% growth respec-
tively (Figure 4.8). This difference however, was not statistically significant.
Figure 4.8: Percentage clonal formation of ARMT1 knockdown clones
and controls grown in soft agar. Cells were seeded at 2000 cells per well in
an agarose solution, then grown for 12 days. Colonies greater than 0.5 mm were
counted. Each bar represents the average of all ARMT1 knockdown clones or
controls, each having been examined nine times over three biological replicates.
Values were plotted with error bars representing standard error of the mean.
Difference in clonal formation between the MCF-7 ARMT1 knockdown clones
and controls was analysed using an unpaired t-test.
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Similar results were seen when the MCF-7 overexpression clones and control
were examined via soft agar assays. The ARMT1 overexpression clones showed
a slight decrease in clonal formation with 0.085% growth, compared to 0.097%
in the control clone. Again, this difference was not statistically significant.
Figure 4.9: Percentage clonal formation of ARMT1 overexpression
clones and control grown in soft agar. Cells were seeded at 2000 cells per
well in an agarose solution, then grown for 12 days. Colonies greater than 0.5
mm were counted. Each bar represents the average of both ARMT1 overex-
pression clones or control, each clone having been examined nine times over
three biological replicates. Values were plotted with error bars representing stan-
dard error of the mean. Difference in clonal formation between MCF-7 ARMT1
overexpression clones and control was analysed using an unpaired t-test.
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4.4.2 DNA damage repair
Perry et.al. (2015) showed that MCF-7 ARMT1 knockdown caused increased
survival after the genotoxic stresses UV, and doxorubicin, compared to con-
trols. In order to investigate this within this study, MCF-7 ARMT1 knockdown
and overexpression clones and controls were exposed to the same levels of geno-
toxic stresses used in the Perry et.al. (2015) study. The clonogenic growth of
the clones were then measured using the same growth and measurement condi-
tions as used in the study.
4.4.2.1 Analysis of post DNA damage clonogenic growth
Both the ARMT1 knockdown clones and the controls showed the same trend
of decreased survival with increased doxorubicin exposure (Figure 4.10 A). Al-
though at each treatment level the ARMT1 knockdown clones showed a de-
crease in survival compared to the control clones, none of these decreases were
statistically significant. This contrasts the findings of Perry et.al. (2015) in which
the ARMT1 knockdown sample showed an increase in survival compared to con-
trols that at the highest treatment point, 500 nM, was at least 30% greater (no
exact figures are given in the paper).
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Figure 4.10: Percentage of clonogenic growth in ARMT1 knockdown
clones and controls (A) and ARMT1 overexpression clones and con-
trols (B) after exposure to doxorubicin. Percentage survival of clones and
controls after exposure to doxorubicin for four hours at concentrations 0 nM,
100 nM, 200 nM, 300 nM, 400 nM, and 500 nM. Percentage survival was cal-
culated by normalising cell counts to the untreated (0 nM) sample cell counts
for each clone. Each point represents the average of three replicates, with error
bars indicating the standard error of the mean. Difference in survival between
MCF-7 ARMT1 knockdown and overexpression clones and respective controls
was analysed using an unpaired t-test.
Similarly, the ARMT1 overexpression clones showed little difference to the
control after exposure to doxorubicin (Figure 4.10 B). Again, both samples fol-
lowed a similar trend with increasing exposure causing decreased survival. The
ARMT1 overexpression clones showed a small decrease in survival compared to
the control at each point, however none of these decreases were shown to be sta-
tistically significant.
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The study measuring clonogenic growth in MCF-7 ARMT1 knockdown
clones and controls after exposure to UV showed very little difference in survival
(Figure 4.11 A). The percentage survival of both the ARMT1 knockdown clones
and controls decreased as exposure increased. The ARMT1 knockdown clones
showed a small decrease in survival compared to the control clones, however this
was not statistically significant. Perry et.al. (2015) reported no difference in sur-
vival between the ARMT1 knockdown clones and controls up to 15 J/m2 of UV
exposure. However, at 20 J/m2 of UV the ARMT1 knockdown clones showed
approximately 10% less survival that the controls, and approximately 20% less
survival at 25 J/m2 of UV (no exact figures are given in the study). The results
of this study do not corroborate with the previously reported findings of Perry
et.al. (2015).
The ARMT1 overexpression clones and control similarly showed little dif-
ference in clonogenic growth after exposure to UV (Figure 4.11 B). Both groups
showed the same trend in decreased survival as exposure increased. However,
the ARMT1 overexpression clones did show a small non significant decrease in
survival compared to the control clones at each point.
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Figure 4.11: Percentage of clonogenic growth in ARMT1 knockdown
clones and controls (A) and ARMT1 overexpression clones and con-
trols (B) after exposure to UV exposure. Percentage survival of clones
and controls after exposure to UV at concentrations 0 J.m−1, 5 J.m−1, 10 J.m−1,
15 J.m−1, 20 J.m−1, or 25 J.m−1. Percentage survival was calculated by normal-
ising cell counts to the untreated (0 J.m−1) sample cell counts for each clone.
Each point represents the average of three replicates, with error bars indicating
the standard error of the mean. Difference in survival between MCF-7 ARMT1
knockdown and overexpression clones and respective controls was analysed using
an unpaired t-test.
4.4.2.2 Analysis of post DNA damage clonogenic IC50
In order to further analyse the clonogenic growth results, the IC50 values were
calculated and compared for each test. The IC50 value is defined as the half
maximal inhibitory concentration of a substance. It is a measure of the concen-
tration needed to inhibit half of the maximum biological response of a substance
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(Beck et al., 2012). In this instance, the IC50 values of the ARMT1 knock-
down and overexpression clones and respective controls after exposure to geno-
toxic stresses are being compared. This is in order to elucidate any difference
ARMT1 expression has on the ability of the genotoxic stresses to reduce clono-
genic growth to 50%.
The IC50 values of ARMT1 knockdown clones and controls treated with
doxorubicin were calculated to be 82.06 nM and 162.0 nM, respectively (Table
4.1). Although the IC50 value for the ARMT1 knockdown clones was lower
than that of the controls, this was not statistically significant (P>0.557). Sim-
ilarly, when treated with UV, the ARMT1 knockdown clones showed a lower
IC50 value than the controls, 164.6 J/m2 and 237.6 J/m2 respectively. Again
however, this was shown not to be statistically significant (P>0.9672). Graphs
showing IC50 curves can be found in Appendix D.
The ARMT1 overexpression clones and controls treated with doxorubicin
showed IC50 values of 122.9 nM and 183.5 nM respectively (Table 4.1). These
values were not significantly different (P>0.548). When the IC50 was calculated
for ARMT1 overexpression clones and control treated with UV, only a value
for ARMT1 overexpression clones was able to be calculated (123.35 J/m2). The
previously mentioned percentage survival of the control clones (Section 1.5.2.1)
did not decrease enough for the IC50 value to be identified. This means the
IC50 values of the ARMT1 overexpression clones and controls treated with UV
can not be compared. Graphs showing IC50 curves can be found in Appendix
D.
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Table 4.1: Clonogenic growth IC50 values and associated P Values.
IC50 values for ARMT1 knockdown and overexpression clones and respective
controls after doxorubicin and UV treatment. Difference in IC50 values were
analysed using an unpaired t-test with P values shown in the table.
Doxorubicin
(nM)
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4.4.2.3 Analysis of post DNA damage non-clonogenic growth
As the analysis of clonogenic growth in this study elucidated results dissimilar
to that of Perry et al. (2015), an endpoint analysis of growth was also under-
taken. MCF-7 ARMT1 knockdown and overexpression clones and controls were
again treated with doxorubicin and UV, then stained with Hoechst 33342 dye
and counted using the Cytation 5 Cell Imaging Multimode Reader.
The ARMT1 knockdown clones showed very little difference in survival
compared to controls when treated with doxorubicin (Figure 4.12 A). Both ARMT1
knockdown clones and control clones showed a similar trend of decreasing sur-
vival after increasing exposure. The percentage survival of the ARMT1 knock-
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down clones was lower than that of the controls at 100 nM and 200 nM, how-
ever this was non significant. Similarly, the ARMT1 overexpression clones and
control showed very similar levels of decreasing survival over increasing doxoru-
bicin dosage (Figure 4.12 B). At 400 nM the ARMT1 overexpression clones had
a decreased survival compared to the controls, however this was not statistically
significant.
Figure 4.12: Percentage survival of ARMT1 knockdown clones and
controls (A) and ARMT1 overexpression clones and controls (B) after
exposure to doxorubicin. Percentage survival of clones and controls after
exposure to doxorubicin for four hours at concentrations 0 nM, 100 nM, 200
nM, 300 nM, 400 nM, and 500 nM. Percentage survival was calculated by nor-
malising cell counts to the untreated (0 nM) sample cell counts for each clone.
Each point represents the average of three replicates, with error bars indicating
the standard error of the mean. Difference in survival between MCF-7 ARMT1
knockdown and overexpression clones and respective controls were analysed
using an unpaired t-test.
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When the ARMT1 knockdown clones and controls were exposed to UV,
very little difference was seen in survival (Figure 4.13 A). Both the ARMT1
knockdown clones and controls showed a decrease in survival over increasing
UV exposure. The survival percentage was very similar between the ARMT1
knockdown clones and controls at each concentration point, other than 25 J/m2.
At this point, the ARMT1 overexpression clones had a higher survival percent-
age than the control clones, however this difference was non significant. The
ARMT1 overexpression clones and control showed similar results when exposed
to UV (Figure 4.13 B). Both the ARMT1 overexpression clones and control
showed decrease in survival percentage over increasing UV exposure. The sur-
vival at each UV concentration point was similar between the ARMT1 over-
expression clones and control. However, at 20 J/m2 and 25 J/m2 the ARMT1
overexpression clones had a small non significant increase in survival compared
to the control clone.
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Figure 4.13: Percentage survival of ARMT1 knockdown clones and
controls (A) and ARMT1 overexpression clones and controls (B) af-
ter exposure to UV exposure. Percentage survival of clones and controls
after exposure to UV at concentrations 0 J.m−1, 5 J.m−1, 10 J.m−1, 15 J.m−1,
20 J.m−1, or 25 J.m−1. Percentage survival was calculated by normalising cell
counts to the untreated (0 J.m−1) sample cell counts for each clone. Each point
represents the average of three replicates, with error bars indicating the stan-
dard error of the mean. Difference in survival between MCF-7 ARMT1 knock-
down and overexpression clones and respective controls was analysed using an
unpaired t-test.
4.4.2.4 Analysis of post DNA damage non-clonogenic growth IC50
The growth analysis IC50 values of ARMT1 knockdown clones and controls
treated with doxorubicin did not show a statistically significant difference (Ta-
ble 4.2). Although the ARMT1 knockdown clones had a lower IC50 than the
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controls, 73.87 and 284.5, respectively, this was found to be non significant. Sim-
ilarly, UV treatment of the ARMT1 knockdown clones showed a lower IC50
value than the controls, 22.18 J/m2 and 48.53 J/m2 respectively. Again however,
this was not statistically significant (P>0.8084). Graphs showing IC50 curves
can be found in Appendix D.
The ARMT1 overexpression clones and controls treated with doxorubicin
showed IC50 values of 112.8 nM and 79.28 nM respectively (Figure 4.1). These
values were not statistically significant (P>0.7563). The IC50 values calculated
for ARMT1 overexpression clones and control treated with UV were again not
statistically significant (P>0.4320), at 11.41 J/m2 and 140.4 J/m2 respectively.
Graphs showing IC50 curves can be found in Appendix D.
Table 4.2: Non-clonogenic growth analysis IC50 values and associ-
ated P Values. IC50 values for ARMT1 knockdown and overexpression clones
and respective controls from doxorubicin and UV treatment. Difference in IC50
values were analysed using an unpaired t-test with P values shown in the table.
Doxorubicin
(nM)














As previous findings had indicated an increased level of senescent cells in MCF-
7 ARMT1 knockdown clones compared to controls (Mason, 2013), this study
aimed to further examine senescence in MCF-7 ARMT1 knockdown clones and
controls. The results did not agree with previous findings (Mason, 2013), and
found no difference in the number of senescent cells in MCF-7 ARMT1 knock-
down clones compared to controls.
It was postulated in this study that ARMT1 may aid cells to enter a senes-
cent state. It has been thought that the onset of senescence can be triggered by
a number of factors; shortening of telomeres, elevated expression of oncogenic
signalling, mitochondrial regression, and DNA damage (Collado and Serrano,
2010; Evan and d’Ada di Fagagna, 2009; Hanahan and Weinberg, 2011), how-
ever, precisely what the key regulators of senescent reprogramming are remains
unclear. A recent study has shown that DNA methyltransferase 1 (DNMT1)-
mediated DNA methylation activity occurs before the display of senescence in
human diploid fibroblasts. Decreased expression of ubiquitin-like with PHD and
ring finger domains 1 (UHRF1), a DNMT1 interacting protein, in part initiated
suppression of (DNMT1)-mediated DNA methylation activity, thus decreasing
senescence initiation (Jung et al., 2017). This information in conjunction with
the idea that Armt1 is a protein carboxyl methyltransferase that targets PCNA
and is linked to the DNA damage response, would suggest that ARMT1 knock-
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down would cause a decrease in senescent induction if any change was to be
seen. As the results of this study showed no significant change in the level of
senescence in MCF-7 ARMT1 knockdown clones compared to controls, it sug-
gests ARMT1 may not play a role in senescence initiation.
The level of senescence in MCF-7 ARMT1 knockdown clones and controls
was also examined when the cells were under stressed conditions. It was thought
that no change in the level of senescence may have been seen between the sam-
ples as they were not in such a condition that senescence normally would be in-
duced. When examined under such senescence-inducing conditions, no difference
was seen between the MCF-7 ARMT1 knockdown clones and controls. This fur-
ther suggests Armt1 may not play a role in senescence initiation.
Although the method used for assessing the level of senescence in the cell
clones is widely used and cited (Debacq-Chainiaux et al., 2009), it is not with-
out limitations. The counting and identifying of senescence associated β-galactosidase
activity in cells is undertaken by human eye. Although the counting in this
study was undertaken using a blind-counting method to remove bias as a con-
founding factor, human error and subjectivity must be taken into account. The
level in colour that the cell must show to be considered senescent is a subjec-
tive factor, and human error during counting could also confound results. Au-
tomated methods of counting and distinguishing blue cells within a population
of cells were thoroughly explored during this study, however no software and
machinery available for use was able to distinguish a blue stained cell correctly
from an unstained cell.
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The results of this study suggest ARMT1 does not play a role in regulating
senescence in MCF-7 cells. However, if this avenue were to be explored further,
an automated system to distinguish the stained cells from the unstained cells
may provide more accurate results. If ARMT1 was found to have an effect on
cellular senescence, it could provide a possible therapeutic target for stopping
the avoidance of senescence in cancer cells.
4.5.2 Cell invasion and metastasis
A required hallmark of cancer cells is the ability to invade tissue and metasta-
sise. This study utilised wound healing as a measure of the cells ability to in-
vade and metastasise.
MCF-7 ARMT1 overexpression clones showed a significant increase in wound
confluence compared to the control clone at each time point measured. Contrar-
ily, analysis of MCF-7 ARMT1 knockdown clones and controls showed no sig-
nificant difference in the rate of wound healing. The knockdown and overexpres-
sion of a gene can not always be expected to cause opposing results, however,
the significant results in wound healing shown between the ARMT1 overexpres-
sion clones and control are limited by the number of clones tested. With only
two ARMT1 overexpression clones and one control clone, it is hard to interpret
these results as being specifically due to the modification of ARMT1. Cell clones
originate from a single cell that incorporates the transfection plasmid. The in-
corporation of the plasmid can cause a disruption to a gene if it inserts within
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its sequence. This may disrupt its translation, and thus can cause a dysregula-
tion to cellular function. This problem is mitigated by using several clones for
each sample and control. As no more samples or controls were available, this
was not an option for this study. The result found in this study of ARMT1
overexpression clones showing an increased wound confluence compared to the
control clone would need to be verified further with more clones before it could
be suggestive of mechanistic involvement.
Other confounding factors in this analysis method come from the creation
of the scratch, and the calculation of would healing. Although the WoundMaker
was used instead of manual scratch in order to reduce variability in scratches,
variation is not eliminated completely. Some difference in size or shape of the
scratch was still seen between wells. The calculation of wound healing may also
confound results, as this is analysed by the IncuCyte confluence metrics soft-
ware. Errors can occur when the mask is applied to areas containing cells, caus-
ing misleading results. In an attempt to mitigate these potential confounding
factors, five technical replicates were used for biological replicates, instead of
three. If available, a laser ablation method of scratching the cell would have
provided a more accurate wound , and electric cell-substrate impedance sens-
ing would have provided a more accurate measure of wound closure (Tamada et
al. 2007, Zordan et al., 2011).
As little is known about ARMT1, no data has been reported regarding a
relationship with cell invasion. As well as repeated wound healing analysis, tran-
swell migration and invasion assays (Boyden chamber) may be of use in order
to grasp a more comprehensive analysis of such a relationship. Boyden cham-
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ber experiments provide analysis of a cells invasive ability to move through a
porous membrane (Boyden, 1962; Restouin et al., 2009), and can be modified
to produce an ’invasive index’ of cells : a rate of invasiveness versus migration
(Marshal, 2011).
If the results of this study were replicated in further clones and other meth-
ods of invasion analysis such as the Boyden chamber, it could indicate a rela-
tionship between ARMT1 and cell invasion. If overexpression of ARMT1 was
proven to cause an increase in the invasion ability of a cell, it could contribute
to the invasion-metastatic cascade of neoplastic cells and aid in cell invasion and
migration.
As the results of this study suggest a possible relationship between ARMT1
expression and the invasion ability of MCF-7 cells, further analysis of ARMT1
in this regard is needed. If ARMT1 expression was shown to increase cell inva-
sion, it would provide a promising therapeutic target for reducing migration of
ER positive breast cancer.
4.5.3 Evasion of growth suppressors
4.5.3.1 Soft agar
The soft agar assay quantifies a cells tumourigenicity by measuring a cells abil-
ity to form colonies in semi-solid agarose gel (Hamburger and Salmon, 1977). In
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this instance, the assay was used to probe the relationship between the dysregu-
lation of ARMT1 and tumour suppression.
Neither the MCF-7 ARMT1 knockdown or overexpression clones showed a
significant difference in anchorage independent growth compared to their respec-
tive controls. A reduction or increase in anchorage independent growth would
indicate ARMT1 was involved in the mechanisms allowing cells to survive with-
out basement membrane signals, and thus tumourigenicity. The lack of signif-
icant differences suggests ARMT1 is not involved in evading or aiding tumour
suppression.
Although the soft agar assay is one of the most rigorous examinations of
anchorage independent growth, it is not without limitations (Borowicz et al.,
2014). The largest area for variation comes from the quantification method.
Here, samples were stained with crystal violet, then colonies greater than 0.5
mm were blind counted by eye. As this is a manual counting method and the
size of colonies are hard to distinguish by eye, human error may effect the re-
sults. Colonies were chosen not to be counted under a microscope, as colonies
grow throughout the agar, meaning a single focus plane will not show all colonies.
Several focus planes can be used to count colonies, however this increases the
risk of double counting colonies and bias relating to focus plane choice.
More automated methods of colony counting exist, such as the use of flu-
orometric dyes. This has previously been achieved by staining the cells with
alamarBlue or tetrazolium dyes then using a plate reader to quantify colonies
(Anderson et al., 2007). This method requires a plate reader capable of focusing
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on several focal planes throughout a culture plate well, meaning it could not be
used in this study.
The results of this study do not suggest ARMT1 is related to the tumour
suppression ability of MCF-7 cells. However, this study is in no way conclusive
of this fact. Further analysis of ARMT1 and its relation to tumour suppression
is needed. An analysis of resistance to apoptosis, and apoptosis regulators could
provide more insight.
4.5.3.2 DNA damage repair
Evading growth suppressors is a hallmark of cancer cells. A key mechanism of
this hallmark is the enhancement of DNA damage response. It allows the cells
to evade DNA-damaging agents by eliminating damaged DNA lesions within the
genome. Perry et al. (2015) reported MCF-7 ARMT1 knockdown clones showed
an increased resistance to DNA damage compared to controls, thus suggesting
ARMT1 plays a role in the cellular response to DNA damage.
In order to assess the cellular response to DNA damage in the MCF-7 ARMT1
knockdown and overexpression clones used in this study, the experimental pro-
tocol used by Perry et al. (2015) were replicated in this study. No significant
difference was found between the ARMT1 knockdown clones and controls when
treated with doxorubicin and UV. Likewise, no significant difference was found
between the ARMT1 over expression clones and their control when treated with
both doxorubicin and UV. The IC50 was evaluated for each set of experiments,
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and produced no significant differences. These results are contrary to those re-
ported by Perry et al. (2015).
It was assumed that the MCF-7 ARMT1 knockdown clones used in this
study would show a similar trend to the results reported in the Perry et al. (2015)
study. Many reasons could exist for the discrepant results. This study used five
ARMT1 knockdown clones and three control clones in order to reduce con-
founding effects of individual clone phenotypes. The Perry et al. (2015) study
only mentions the use of one MCF-7 ARMT1 knockdown clone and one control
clone. The lack of multiple clones dictates a possibility that the difference seen
is not due to the ARMT1 dysregulation, but to a dysregulation of another gene,
caused by the plasmid insertion.
Additionally, the Perry et al. (2015) study showed no statistical analysis
of their data. The graphs represent mean colony numbers from three replicates
with error bars presenting standard error of the mean, however whether or not
the points are significantly different is not shown. The axis of the graphs pre-
senting the data have been log transformed, with each graph being transformed
to a different log base, further increasing the analysis difficulty of the data. The
lack of biological replicates in this study also calls into question the significance
of the presented data.
Possible contamination or changes to the parent MCF-7 cell line used in
this study or the Perry et al. (2015) paper could also be to blame for the dis-
crepant results. Cell line contamination has plagued scientists since the 1950s
when it was first discovered. In 1967, Stanley Gartler reported 18 cell lines of
110
supposed independent origins were all in fact HeLa cells (Gartler, 1967). The
latest report from the International Cell Line Authentication Committee re-
leased December 1st 2016 now lists 488 cell lines as misidentified or contam-
inated (ICLAC, 2017), highlighting the need for constant cell line validation.
Misidentification and cross contamination of cell lines is an unsolved issue in
current research, even though cell line authentication has been widely recom-
mended for years (Masters, 2012; Nardone, 2007). Misidentification of cell lines
can lead to studies producing non reproducible data, adding misinformation to
the literature (Neilmark, 2015). Possible contamination occurring to the parent
MCF-7 cell line used to create the Perry et al. (2015) clones, or the MCF-7 cell
line used to create the clones in this study could have occurred. This would lead
to non reproducible results, a possible explanation for the discrepant findings
of this study. Immediately prior to the creation of the stable clones used in this
study, the parent MCF-7 cell line was STR genotyped and found to be consis-
tent with the MCF-7 genotype, thus making it unlikely that the clones used do
not represent MCF-7 cells. Official authentication of the Perry et al. (2015) cell
line would combat this potential confounding factor.
The results of this study, contrary to the results reported by Perry et al.
(2015), indicate ARMT1 is not involved in the cellular response to DNA dam-




The previous findings showing an increase in senescence associated β-galactosidase
activity in ARMT1 knockdown clones (Mason, 2013) was not replicated in this
study. Instead, no significant difference was seen between the MCF-7 ARMT1
knockdown clones and controls when the cells were analysed under normal and
stressed conditions.
Analysis of wound healing produced no significant difference between the
MCF-7 ARMT1 knockdown clones and controls. However, a significant increase
in wound confluence was seen in the MCF-7 ARMT1 overexpression clones com-
pared to the control, indicating a possible relationship between ARMT1 and cell
invasion. This connection needs further investigation through increased clone
number and analysis methods however, before a conclusion can be made.
Dysregulation of ARMT1 had no effect on anchorage independent growth
in this study. Neither the MCF-7 ARMT1 knockdown or overexpression clones
showed a significant difference in soft agar colony formation, compared to con-
trols. This suggests ARMT1 is not involved in aiding or hindering MCF-7 cells
evading growth suppressors.
The results reported by Perry et.al. (2015) showing increased clonogenic
growth post genotoxic stress when ARMT1 is knocked down, have not been
replicated in this study. The results of this report found no significant difference
between both the ARMT1 knockdown clones and controls, and the ARMT1
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over expression clones and their control. Similarly, no significant difference was
seen in non-clonogenic growth post genotoxic stress between both the ARMT1
knockdown clones and controls, and the ARMT1 over expression clones and
their control. When the IC50 was analysed for each set of results, no significant
difference was found in any treatment groups. Together, these results suggest
ARMT1 may not play a role in the cellular response to DNA damage repair as
reported by Perry et.al. (2015).
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Chapter 5
Expression Analysis of Related
Genes
5.1 Study rationale
As previously discussed in Section 1.2.4, Dunbier et al. (2011) identified a cor-
relation between ESR1 expression and ARMT1 expression using publicly avail-
able data sets, and cultured MCF-7 cells (Dunbier et al., 2011). Additionally,
the authors identified two other genes (CCDC170 and RMND1 ) that also lie
within the breast cancer susceptibility locus identified directly upstream of the
ESR1 gene on chromosome 6q25.1, to be correlated with its expression (Zheng
et al., 2009; Stacey et al., 2010; Cai et al., 2011; Dunbier et al., 2011). Inter-
estingly, transcriptional co-activation is not thought to be directly mediated by
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oestrogen, as treatment with an oestrogen antagonist does not affect the gene’s
expression, or correlation with ESR1. The correlation was shown more likely to
be driven by transcriptional regulation, rather the genomic alterations (Dunbier
et al., 2011). However, to date, the mechanism underlying this co-expression is
not well understood. Although ARMT1 does not have any known direct role in
transcription, an indirect effect on the other genes through some feedback loop
remains possible.
For this reason, transcriptional analysis of ESR1, CCDC170, and RMND1
after dysregulation of ARMT1 could provide some insight into the mechanisms
underlying the correlation. Analysis of the two downstream ESR1 responsive
genes, GREB1 and TFF1, may provide confirmation of its biological relevance,
as their transcription is regulated by oestrogen, therefore their expression mir-
rors that of ESR1 (Rae et al., 2005; Green et al., 2007).
5.2 Expression analysis of related genes
Quantitative real-time polymerase chain reaction (qPCR) was used to analyse
the relative expression levels of ARMT1, CCDC170, ESR1, RMND1, GREB1,
and TFF1 in MCF-7 ARMT1 knockdown and MCF-7 ARMT1 overexpression
clones and controls. The Minimum Information for Publication of Quantitative
Real-Time PCR Experiments(MIQE)were adhered to when interpreting results
(Bustin et al., 2009). The efficiencies of probes were evaluated for each probe
set, with representative values being found in Appendix B. The expression lev-
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els of the genes of interest: ARMT1, CCDC170, ESR1, RMND1, GREB1, and
TFF1 were normalised to the geometric mean of two reference genes FKBP15
and PUM1. These two genes have previously been shown to be stably expressed
in breast cancers (Drury et al., 2009). The constitutive expression of these two
reference genes were confirmed in the cell line used in this experiment prior to
investigation beginning (Dunbier, personal communication).
5.2.1 MCF-7 ARMT1 knockdown expression analysis
The relative expression of ARMT1, CCDC170, ESR1, RMND1, GREB1, and
TFF1 for three biological replicates of MCF-7 ARMT1 knockdown clones and
controls showed interesting results (Figure 5.1). The results show a decrease in
expression of ARMT1, CCDC170, ESR1, RMND1, and GREB1, in every MCF-7
ARMT1 knockdown clone compared to the controls. However, for TFF1, only
four of the five MCF-7 ARMT1 knockdown clones showed a decreased expres-
sion compared to both controls. The first MCF-7 ARMT1 knockdown clone
showed expression of TFF1 higher than that of the first control and lower than
that of the second. A trend of expression knockdown of each of the genes within
the chromosome 6q25.1 locus is evident in each of the MCF-7 ARMT1 knock-
down clones compared to the controls.
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Figure 5.1: ARMT1, CCDC170, ESR1, RMND1, GREB1, and TFF1
expression in MCF-7 ARMT1 knockdown clones and respective con-
trols. Each bar represents the average of nine replicates collected over three
biological replicates. Values from each biological replicate were Normalised to
the reference genes FKBP15 and PUM1, then centred. Values were plotted with
error bars representing standard error of the mean.
Normalised and centred data from three biological replicates of MCF-7
ARMT1 knockdown clones and controls, comparing the mean expression of all
MCF-7 ARMT1 knockdown clones to the mean expression of all of the control
clones for each gene of interest showed significant results (Figure 5.2). These
cumulative data show a significant decrease in expression of these genes in the
MCF-7 ARMT1 knockdown cells compared to the controls, across each of the
genes of interest.
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Figure 5.2: Averaged expression of ARMT1, CCDC170, ESR1,
RMND1, GREB1, and TFF1 expression in MCF-7 ARMT1 knock-
down clones and respective controls. Each bar represents the average ex-
pression of all ARMT1 knockdown clones or all control clones. Each of the indi-
vidual samples consist of nine replicates collected over three biological replicates.
Values from each biological replicate were normalised to the reference genes
FKBP15 and PUM1, then centred. Values were plotted with error bars repre-
senting standard error of the mean. Differential expression between ARMT1
knockdown clones and controls was analysed using an unpaired t-test. Expres-
sion values found to be statistically significant between the ARMT1 knockdown
clones and control clones are indicated on the graph with summarised P values:
*<0.05, **<0.01, ***<0.001, ****<0.0001.
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The MCF-7 ARMT1 knockdown clones showed a significant 7.22 fold de-
crease in the expression of ARMT1 (P<0.0001), compared to the controls. Like-
wise, the MCF-7 ARMT1 knockdown cells also showed a significant 1.73 fold
decrease of CCDC170 (P<0.0014), a significant 2.02 fold decrease of ESR1 (P<0.0001),
a significant 1.65 fold decrease of RMND1 (P<0.0031), a significant 1.78 fold
decrease of GREB1 (P<0.0009), and a significant 1.51 fold decrease of TFF1
(P<0.0038), compared to control clones.
5.2.2 MCF-7 ARMT1 overexpression expression analysis
The relative expression of ARMT1, CCDC170, ESR1, RMND1, GREB1, and
TFF1 for three biological replicates of MCF-7 ARMT1 overexpression clones
and controls were measured (Figure 5.3). These results show an increase in ex-
pression of ARMT1 in the MCF-7 ARMT1 overexpression clones compared
to their control, however no change to the expression of CCDC170, ESR1, and
RMND1 was shown. The MCF-7 ARMT1 overexpression clones showed a small
non significant increase in GREB1 and TFF1 expression compared to their con-
trol, however the increase is small compared to the level of error shown by error
bars (standard error).
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Figure 5.3: ARMT1, CCDC170, ESR1, RMND1, GREB1, and TFF1
expression in MCF-7 ARMT1 overexpression clones and respective
controls. Each bar represents the average of nine replicates collected over three
biological replicates. Values from each biological replicate were Normalised to
the reference genes FKBP15 and PUM1, then centred. Values were plotted with
error bars representing standard error of the mean.
Normalised and centred data from three biological replicates of MCF-7
ARMT1 overexpression clones and controls comparing the mean of all MCF-7
ARMT1 overexpression clones to the mean expression of the control showed lit-
tle significant data (Figure 5.4). These cumulative data show a significant 1.82
fold increase in ARMT1 expression (P<0.0145 ) in the MCF-7 ARMT1 overex-
pression cells compared to the controls. This however, was the only significant
increase or decrease in gene of interest expression between the MCF-7 ARMT1
overexpression clones and their controls. An increase in expression in MCF-7
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ARMT1 overexpression clones was seen in ESR1, GREB1, and TFF1 compared
to the control, however these increases were non significant (P<0.59, P<0.454,
and P<0.403, respectively). A decrease in expression in MCF-7 ARMT1 overex-
pression clones was seen in CCDC170 and RMND1, however these results were
again found to be non significant (P<0.889 and P<0.842, respectively).
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Figure 5.4: Averaged expression of ARMT1, CCDC170, ESR1,
RMND1, GREB1, and TFF1 expression in MCF-7 ARMT1 over-
expression clones and respective controls. Each bar represents the average
expression of all ARMT1 overexpression clones and the control clone. Each of
the individual samples consist of nine replicates collected over three biological
replicates. Values from each biological replicate were Normalised to the refer-
ence genes FKBP15 and PUM1, then centred. Values were plotted with error
bars representing standard error of the mean. Differential expression between
ARMT1 overexpression clones and control was analysed using an unpaired t-
test. Expression values found to be statistically significant between the ARMT1
overexpression clones and control are indicated on the graph with summarised P
values: *<0.05, **<0.01, ***<0.001, ****<0.0001.
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5.3 Discussion
The genes ARMT1, CCDC170, and RMND1 have been shown to be co-expressed
with ESR1 (Dunbier et al., 2011), and to lie within a breast cancer susceptibil-
ity locus at chromosome 6q25.1, directly upstream of the ESR1 gene (Zheng
et al., 2009; Stacey et al., 2010; Cai et al., 2011; Dunbier et al., 2011). As the
mechanism driving this correlation is poorly understood, an investigation as
to the effects of dysregulation of ARMT1 on the other genes within the chro-
mosome 6q25.1 breast cancer susceptibility locus was undertaken in this study.
Along with this, the expression of the two oestrogen-regulated genes GREB1
and TFF1 (Rae et al., 2005; Green et al.,2007) were examined in order to fur-
ther investigate any effect on ER signalling.
As the shRNAs incorporated in the GIPZ plasmid used to create the MFC-
7 ARMT1 knockdown clones were targeted specifically to ARMT1, no change in
the expression of the other genes of interest were expected. Examination of the
MCF-7 ARMT1 knockdown clones in this study showed a statistically signifi-
cant decrease in each of the genes in the chromosome 6q25.1 locus when the ex-
pression of ARMT1 was suppressed. The trend of decreased expression is clear
when analysing these clones both individually and in combination. The only
difference to this trend comes from the expression of TFF1 in the first MCF-
7 ARMT1 knockdown clone, as its expression is higher than that of one of the
controls, however its expression is still lower than that of the mean expression of
both controls. These data show a clear decrease in ESR1, CCDC170, RMND1,
GREB1, and TFF1 expression in MCF-7 ARMT1 knockdown clones compared
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to controls when ARMT1 is knocked down. The decrease in expression of ESR1
is further substantiated by the reduction in expression of GREB1 and TFF1 as
these genes are oestrogen-regulated genes.
However, the MCF-7 ARMT1 overexpression clones in this study showed
no significant change in the expression of any of the genes of interest, other than
the expression of ARMT1 which was, as to be expected, significantly higher
in the MCF-7 ARMT1 overexpression clones than in the controls. One possi-
ble explanation for this could be due to the level of ARMT1 overexpression in
these cells compared to the level of ARMT1 knockdown in the MCF-7 ARMT1
knockdown clones. The level of overexpression produced in the MCF-7 ARMT1
overexpression clones used in this study averaged a 1.82 fold increase in ARMT1
expression compared to the control, whereas the level of knockdown produced in
the MCF-7 ARMT1 knockdown clones averaged a 7.22 fold decrease in ARMT1
expression compared to controls. This lower level of ARMT1 expression disrup-
tion observed in the MCF-7 ARMT1 overexpression clones could explain why
these clones are not able to elucidate a difference in the expression of the other
genes in the chromosome 6q25.1 locus, such as was seen in the MCF-7 ARMT1
knockdown clones.
Alternatively, the MCF-7 ARMT1 overexpression clones may not show ex-
pression changes in the other genes within the chromosome 6q25.1 locus because
genetic knockdown and overexpression can not always be expected to cause mir-
rored effects. A study by Ma et al. (2016) showed the knockdown and overex-
pression of ferroptosis in a number of breast cancer cell lines including MCF-7
cells cause opposing effects on cell death, whereas Wang et al. (2014) showed
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the overexpression of SRPK1 in cancer cells to cause a dominant negative ef-
fect by silencing part of the protein complex that does not form when SRPK1 is
knocked down, therein causing the same phenotypic effect as that of a SRPK1
knockdown. It is also commonly found that the knocking down of a certain gene
will affect phenotype, but over expressing the same gene will not cause a change,
and vice versa. A recent example of this comes from a study by Chiang et al.
(2015), where they showed knocking down PTEN in MCF-7 cells caused an in-
crease in growth rate, however over expressing the same gene caused no change.
It is possible that reducing the expression of ARMT1 in MCF-7 cells will cause
an effect on the expression of the other genes within the chromosome 6q25.1 lo-
cus, but increasing the expression of ARMT1 in MCF-7 cells will not.
Another possible explanation for the MCF-7 ARMT1 overexpression clones
not showing a significant change in the expression of the other chromosome
6q25.1 genes could come from their method of generation. In order to assess the
strength of plasmid incorporation, a double HA tag was added to the plasmid
to make the protein viable for western blot analysis via an anti-HA tag anti-
body. As the tag is attached to the ARMT1 protein, it is possible this tag at-
tachment is altering the functionality of the protein, therefore affecting its func-
tion. Examples of HA tags affecting protein function have been shown in many
instances, such as an HA tag abolishing the glucose-uptake activity of exoge-
nous SGLT1 proteins (Huang et al., 2013), or an HA tag impending ATP9-5
from restoring mitochondrial function in atp9 yeast (Sellem et al., 2016). As
very little is known about the ARMT1 protein and its function, it is also pos-
sible the protein requires intracellular localisation within the cell to, for exam-
ple, the nucleus. If the protein was functional in the nucleus, the presence of the
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double HA tag within the protein could be stopping its intracellular localisation
there, and thus stopping it from functioning. If ARMT1 is in some way respon-
sible for the regulation of the other genes within the chromosome 6q25.1 locus,
as could be concluded from the MCF-7 ARMT1 knockdown clones and control
data, then the presence of the HA tag within the ARMT1 overexpression clones
could be halting this interaction from occurring, and thus be the reason that no
difference in seen in the expression of the other genes in the chromosome 6q25.1
locus.
It is possible to conclude from the MCF-7 ARMT1 knockdown clone and
control data that the level of expression of ARMT1 could have an effect on level
of expression of the other genes within the chromosome 6q25.1 locus. This is
made evident by the mirrored knockdown of the other genes within the chro-
mosome 6q25.1 locus when ARMT1 is knocked down. This occurrence would
be the case if ARMT1 was acting as a transcription factor to the other genes
within the chromosome 6q25.1 locus, including ESR1. This together with previ-
ously reported findings from Dunbier et al. (2011) that ARMT1 was positively
correlated with a proliferation metagene in tumours, and that siRNA inhibi-
tion of ARMT1 suppressed proliferation in MCF-7 cells under oestrogen de-
prived conditions, suggest a possible positive transcription feedback loop be-
tween ARMT1 and ESR1. It is possible that oestrogen presence in a cell drives
the transcription of ARMT1, which could result in oestrogen production via en-
zymes involved in its synthesis. This would mean that under oestrogen depriva-
tion, little or no ARMT1 would be transcribed, and thus little or no oestrogen
would be transcribed, thus reducing cell proliferation. This would also explain
the presence of ARMT1 in the tumour metagene, as it would be responsible
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for transcription of ESR1. It is also possible that ARMT1 in some way regu-
lates the expression of CCDC170 and RMND1, but as very little is known about
these genes and their function, it is hard to tell what the effect or reason for this
is.
ARMT1 could also be causing degradation of ESR1, CCDC170, and RMND1
mRNA transcripts. Three categories of degradation mechanisms exist: deadenylation-
dependent decay, deadenylation-independent decay, and endonuclease-mediated
decay (Garneau et al., 2007). For deadenylation-dependent decay, either the
5’ 7-methylguanosine cap or the 3’ poly(A) tail of the mRNA is compromised,
leading to decay (Garneau et al., 2007). Deadenylation-independent decay is
due to decapping caused by autoregulatory mechanisms that include the recruit-
ment of decapping regulators (Badis et al., 2004). Lastly, endonuclease-mediated
decay involves the cleavage of mRNA through endonucleases (Gatfield and Iza-
urralde, 2004; Stevens et al., 2002). It is possible that ARMT1 is acting as a
decapping regulator, or an endonuclease, targeting the ESR1, CCDC170, and
RMND1 mRNA transcripts. This would cause a decrease in expression of these
genes, as is seen in this study.
Another possible reason for the knockdown of the other genes seen in the
MCF-7 ARMT1 knockdown clones could be an ESR1 fusion. A recent study
from Tan et al. (2017) has reported a ESR1 -ARMT1 fusion found through ge-
netic analysis of breast tumours. The study examined 416 breast tumours and
found an ESR1 -ARMT1 fusion in one sample. Interestingly, this sample did
not have any mutations to the ESR1 gene itself. This finding could explain
why the expression of ESR1 was reduced when ARMT1 was knocked down,
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as ARMT1 lies upstream of ESR1, meaning transcription would start from the
ARMT1 end and thus be halted under exposure to shRNAs targeted towards
ARMT1. Theoretically, if the gene fusion of ESR1 -ARMT1 included CCDC170
also, this would explain the decrease in expression of this gene, as it lies down-
stream of ARMT1 and upstream of ESR1. ESR1 -CCDC170 gene fusions have
themselves been shown to exist in a number of breast tumours and cell lines,
including MCF-7. The fusion variants were shown to be of differing lengths be-
tween samples, indicating different genomic regions included in the fusion (Veer-
araghavan et al., 2015). This explanation however, would not explain the de-
crease in expression of RMND1, as it lies upstream of ARMT1. Further research
is needed in order to investigate the specific nature of the ESR1 -ARMT1 fusion
reported by Tan et al. (2017), as strong correlations between recurrent gene fu-
sion and tumour subtypes has made them ideal for diagnostic purposes. If the
claim of this fusion can be substantiated further, it could be a useful tool for
tumour subtype diagnostics.
Although a definite trend in the decrease of expression of the chromosome
6q25.1 genes is able to be seen in the MCF-7 ARMT1 knockdown clones, the
level of knockdown is not as strong in the other genes as in ARMT1 itself. ARMT1
itself was shown to have a 7.22 fold decrease in expression, whereas the CCDC170,
ESR1, RMND1, TFF1, and GREB1 showed a 1.73, 2.02, 1.65, 1.78, and 1.51
fold decrease respectively. As the decrease in expression is not as great in the
other genes as in ARMT1, it suggests the regulation of expression of these genes
is not solely due ARMT1, and must be under the control of another regulatory
element also, otherwise the decrease in expression would be expected to be sim-
ilar to that of ARMT1. However, a trend is nonetheless evident showing the
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expression level of ARMT1 has an effect on the expression of the other genes
within the chromosome 6q25.1 locus.
In order to continue investigation into the effect of the dysregulation of
ARMT1 on the other genes within the chromosome 6q25.1 locus, a further study
examining the effects of over expressing ARMT1 in MCF-7 could be under-
taken, using clones with a stronger level of overexpression. Another logical step
to take would be a protein expression analysis of ARMT1, ESR1, and the other
genes studied, in order to verify that the knockdown observed at the mRNA
level is being translated to the protein level. If these findings do translate to
protein level, ARMT1 could be a potential therapeutic target when aiming to
reduce expression of ESR1. The use of Affymetrix expression arrays could also
provide further understanding of the observed expression changes.
5.4 Conclusion
This study produced surprising results with the knockdown of ARMT1 in MCF-
7 clones by ARMT1 -targeted shRNAs being associated with a decrease in ex-
pression of CCDC170, ESR1, RMND1, GREB1, and TFF1. This finding is strength-
ened by the decrease in expression of GREB1 and TFF1, two oestrogen-regulated
genes. Many possible reasons of this finding exist, however as little is known
about ARMT1, these require further exploration.
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Chapter 6
General discussion and conclusions
This study utilised MCF-7 ARMT1 knockdown and overexpression clones to
study the function of ARMT1. No relationship was found between ARMT1
and cell doubling time, cellular senescence, or anchorage independent growth.
A significant increase in cell invasion was found in the ARMT1 overexpression
clones. However, no difference was seen between the ARMT1 knockdown clones
and controls. Neither the MCF-7 ARMT1 knockdown or overexpression clones
showed a difference in clonogenic growth after exposure to genotoxic stress, con-
trary to previously published results (Perry et al., 2015). A significant decrease
in the expression of CCDC170, ESR1, RMND1, GREB1, and TFF1 was found
in the ARMT1 knockdown clones, but no change to the expression of these
genes were seen in the ARMT1 overexpression clones.
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6.1 Phenotypic analysis of ARMT1 dysregula-
tion
This study attempted to reveal a phenotypic effect of ARMT1 dysregulation in
MCF-7 cells. Together, the cell proliferation rate, cellular senescence levels, and
anchorage independent growth in the clones studied indicate ARMT1 dysregula-
tion does not affect replicative immortality, or the evasion of growth suppressors
in MCF-7 cells. However, these suggestions are not conclusive as further analysis
methods are required to completely eliminate the possibility of ARMT1 caus-
ing disruption to these hallmarks. Cell invasion analysis of ARMT1 knockdown
clones and controls showed no significant difference, however, ARMT1 overex-
pression clones showed a significant increase in cell invasion compared to control.
This finding is of limited validity however, due to the limited sample size exam-
ined. Nonetheless, it does indicate an area of research requiring further analysis.
The analysis of the recognised hallmarks of cancer were not exhaustive in
this study. Sustaining proliferative signalling, resisting cell death, inducing an-
giogenesis, deregulating cellular energetics, and avoiding immune destruction
were not analysed. Analysis of these hallmarks may help to discover the func-
tion of ARMT1, and allude to the reason for its co-expression with ESR1.
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6.2 MCF-7 ARMT1 knockdown clones did not
show an increased resistance to genotoxic stress
The analysis of ARMT1 knockdown in MCF-7 cells in this study showed con-
trasting results to those in the Perry et al. (2015) paper. Although reasons exist
that may explain the difference seen, doubt has been cast on the validity of the
reported findings. Analysis of the validity of scientific work has led to the ’Pro-
teus Phenomenon’. This states that early stage hypothesis generating molecular
research often produces sequences of extreme opposite results (Ioannidis et al.,
2005). As very little is known about ARMT1 and its function, current research
focussing on the gene is early stage research, and this phenomenon may apply.
The lack of replicates and statistics, and the data being displayed on a logged
axis which emphasise the difference in the Perry et al. (2015) study reduces the
credibility of the reported findings.
Further analysis of ARMT1 is required. There is reason to warrant a repli-
cation of clonogenic analysis post DNA damage, however, other methods of
DNA damage analysis should also be considered. Single-cell gel electrophoresis
could provide valuable information, as it allows for the detection of DNA dam-
age repair by quantification of damage remaining at intervals after genotoxic
exposure (Collins et al., 2004).
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6.3 MCF-7 ARMT1 knockdown clones show de-
creased expression of related genes
Oestrogen receptor status is a key prognostic marker in breast cancer, and the
target of a number of therapies. However, little is known about the mechanisms
that cause an increase in ER expression in ER+ breast cancer, with only 14-20%
due to ESR1 amplification (Holst et al., 2007; Moelands et al., 2010; Nielsen
et al., 2011). This study has shown a decrease in the expression of ARMT1
in MCF-7 cells to cause a decrease in the expression of ESR1, CCDC170, and
RMND1. The oestrogen responsive genes GREB1 and TFF1 also showed a
decrease in expression. These findings suggest ARMT1 is involved in the reg-
ulation of the other genes within the chromosome 6q21.5 locus. The ARMT1
overexpression clones did not show an increase in the genes that were effected in
the ARMT1 knockdown clones. Reasons for this have been discussed previously
(Section 5.3).
Interestingly, the decrease in ESR1 seen in the ARMT1 knockdown clones,
validated by the reduced expression of GREB1 and TFF1, have no effect on the
growth rate of the clones (Section 3.4). Doubling time analysis showed no sig-
nificant difference between the ARMT1 knockdown clones and controls. Hypo-
thetically, a decrease in ESR1 would reduce the amount of oestrogen bound to
cells, thus decreasing differentiation, proliferation and growth, as oestrogens are
known to regulate these factors (Johnson and Dowsett, 2003).
The lack of doubling time change in the ARMT1 knockdown clones could
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be due to modifications in protein kinase-signalling pathways. The decreased
expression of ESR1 may have forced the cells to select for increased expression
of protein kinase-signalling pathways, such as the PI3K/AKT/MTOR pathway,
the Ras-Raf-MEK-ERK pathway, or the JAK/STAT pathway. These pathways
which mediate post-translational modifications are known to be rapidly acti-
vated by oestrogen signalling (Hammes et al., 2007). These pathways are also
regulated by a number of kinases, phosphatases, and various exchange proteins
(Chappell et al. 2011). Deregulation of any of the signalling factors can lead
to cell growth and proliferation that is unrestrained (Steelman et al. 2008; Mc-
Cubrey et al. 2008). The decrease in ESR1 expression in the ARMT1 knock-
down cells may have caused a selection for cells that have increased expression
of one or many such pathways, in order to maintain an increased level of cell
growth and proliferation. This would thus mean the doubling time of the cells
would maintain a similar rate to the control cells, however their growth would
be controlled by different factors. Further analysis of the factors mediating such
pathways is needed to fully understand this finding.
Continued growth after oestrogen modulation is not a new phenomenon.
Up to 40% of women who receive adjuvant tamoxifen treatment for ER+ breast
cancer relapse within five years (Houghton, 2006), and approximately 20% that
receive aromatase inhibitor treatment relapse within 10 years (Dowsett et al.
2010; Sotiriou et al., 2006). The response and resistance to these endocrine ther-
apies is poorly understood, however de novo resistance and acquired resistance
have been proposed as resistance mechanisms (Gao et al., 2014). Oestrogen de-
privation in breast cancer lines has been used to study acquired resistance, re-
vealing mechanisms of endocrine resistance (Chan et al., 2002). Such mecha-
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nisms include mutations to the ESR1 region that drive constitutive signalling
(Robinson et al., 2013), increased activation of ER co-activators (Ali and Coombes,
2002), and down regulation of ER co-repressors (Lavinsky et al. 1998). Activa-
tion of growth factor related signal transduction pathways (epidermal growth
factor (EGF), MAP kinase, insulin- like growth factor-I (IGF-1)) have been
postulated to be involved in endocrine therapy resistance (Ali and Coombes,
2002; Lupien et al. 2010; Gururaj et al., 2010), however there is little clinical
evidence for this. Although these resistance mechanisms occur after a period of
years rather than immediately, their existence suggests carcinogenic cells have
the ability to regain constitutive growth signals after ESR1 mediation, as has
been postulated to be occurring in the ARMT1 clones used in this study.
A western blot analysis of the ER expression in the ARMT1 knockdown
clones and controls would provide further evidence into how these cells are main-
taining constitutive growth. If the ARMT1 knockdown clones showed a de-
crease in ESR1 protein expression, the uncontrolled growth would most likely
be due to an increase in the downstream signalling of ESR1, for example, the
PI3K/AKT/MTOR pathway or the Ras-Raf-MEK-ERK pathway. If the ARMT1
knockdown clones showed no difference the protein expression of ESR1, it could
indicate that decreased ARMT1 expression was causing a change to the ESR1
mRNA product that caused it to no longer be bound by the ESR1 primer probe
set used for QPCR analysis in this study. The changes to the ESR1 mRNA
product would then be causing no structural differences to the ESR1 product,
or causing a change that does not affect its function. This is another possible
explanation for the decrease in ESR1 expression not causing a change to growth
rate of the ARMT1 knockdown clones.
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CCDC170 and RMND1 also showed decreased expression in the ARMT1
knockdown clones. As very little is known about these genes, a prediction of any
effects their down regulation may cause is difficult. As their expression mirrored
that of ESR1 after ARMT1 knockdown, it is possible to conclude they are un-
der the same transcriptional regulation as ESR1, and that this regulation is in
some way controlled by ARMT1 presence. Analysis of CCDC170 and RMND1
overexpression and knockdown effects could help to reveal the functions of these
genes, which could in turn expose the reason for their coexpression with ESR1.
6.4 Clinical implications and future directions
Breast cancer is a heterogeneous disease. Diversity exists not only within in-
dividuals, but within tumours also, complicating research and highlighting the
need for a better understanding of the genetic basis of the disease (Burrel et
al., 2013). ER+ breast cancer patients can show vastly different tumour ge-
netics (Bertos and Park, 2011; Martelotto et al., 2014). The status of oestro-
gen receptor positive is given to patients whose tumours consist of at least 1%
cells exhibiting the ER receptor. This low threshold results in many cases where
the majority of cells in the tumour do not show the molecular features of ER+
breast cancers (Bertos and Park, 2011). Intra-tumour heterogeneity, in which
sub-populations of cells within a tumour have different genotypes and pheno-
types, further complicate breast cancer analysis (Gerlinger et al., 2012; Navin et
al., 2010).
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The findings here, are founded from one cancer cell line, MCF-7. As can-
cers are widely heterogeneous, an important first step for the furthering of this
research would be to examine the effects of ARMT1 knockdown and overexpres-
sion in other cell lines. Although cell lines are a convenient model for experi-
mental work, further research would also require examination of heterogeneous
cells in a tumour mass. Responses are often found to be stronger in homoge-
neous cell lines than in heterogeneous tumours (Dixon, 2014), as cell lines lack
the complexities of cancer tumours (Dixon, 2014; Larionov and Miller, 2009).
The local tumour environment also affects therapeutic response, as cancer cells
interact with the local tumour environment and immune cells (Junnttila and
Sauvage, 2013; Dixon, 2014; Burrell et al., 2013). For theses reasons, in vitro
cell line work can be strengthened by the use of in vivo mouse models and hu-
man biopsies. If mouse models with an ARMT1 knockdown showed mirrored
knockdown of the other genes of interest, this would be more indicative of pro-
cesses occurring within human tumours.
The use of the CRISPR/Cas9 system could also provide useful tools for the
study of ARMT1 knockdown. Using nonhomologous end joining, ARMT1 could
be completely removed from the genome of cells (Wang et al. 2013; Cong et al.,
2013). This would improve the current system as the shRNA knockdown does
not eliminate the expression of ARMT1 completely. A complete knockout of the
gene may produce stronger phenotypic or genetic effects that are easier to ex-
amine. A mirrored knockdown effect observed in a CRISPR/Cas9 model would
be indicative of ARMT1 acting as a transcriptional regulator, rather than hav-
ing RNA, DNA, or protein interactions with the gene. As the DNA would be
removed from the genome of the cell, ARMT1 -ESR1 fusions would no longer be
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possible, and as no mRNA and thus protein would be made, degradation of the
CCDC170, ESR1, RMND1 mRNA transcripts is unlikely.
This study has unearthed potentially unreproducible data in a study of
ARMT1 (Perry et al., 2015). If the reportings of the Perry et al. (2015) are in-
deed unreproducible, doubt is cast on ARMT1 being involved the cellular re-
sponse to DNA damage. Further investigations into ARMT1 are needed before
conclusions can be made regarding the gene.
The findings of this study, although not conclusive, do suggest a link be-
tween ARMT1 expression and the expression of the other genes within the chro-
mosome 6q25.1 locus, CCDC170, ESR1, and RMND1. A study of the ARMT1
protein and subsequent characterisation may be helpful for predicting its func-
tion and effect on cell behaviour. ARMT1 protein-DNA, protein-RNA, or protein-
protein interactions, could be the key mechanism behind the observed decrease
in CCDC170, ESR1, and RMND1 expression. If ARMT1 was found to regulate
CCDC170, ESR1, and RMND1 expression in ER+ breast cancers, there is po-
tential for the gene to be manipulated into a therapeutic target to reduce ESR1
expression.
6.5 Summary
Overall, this study has shown that dysregulation of ARMT1 in breast cancer
causes little change to the phenotypic features assessed, but rather induces a
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change to the expression of the three adjacent genes ESR1, CCDC170, and RMND1.
In this study, dysregulation of ARMT1 caused no change to the doubling
time of MCF-7 cells. Likewise, the initiation of cellular senescence was not af-
fected, and the anchorage independent growth did not differ between the ARMT1
knockdown clones and controls. A trend towards increased cell invasion was ob-
served between the MCF-7 ARMT1 overexpression clones and control, however
this finding needs repeating in a larger pool of clones before ARMT1 overex-
pression can be conclusively linked to increased cell invasion.
The results produced by Perry et al. (2015) were not replicated in this
study. Doxorubicin and UV exposure produced no significant difference in both
the growth and clonogenic growth of the MCF-7 ARMT1 knockdown and over-
expression clones compared to respective controls. Further investigation is needed
in order to understand the relationship between ARMT1 and DNA damage re-
pair.
Expression analysis of MCF-7 ARMT1 knockdown clones showed a de-
crease in the expression of CCDC170, ESR1, RMND1, GREB1, and TFF1, sug-
gesting ARMT1 is involved in the regulation of these genes. This novel finding
needs further analysis in order to understand the underlying mechanism. Under-
standing how a decrease in ARMT1 expression is mirrored in ESR1 expression
could lead to a potential therapeutic target for ER+ breast cancer patients.
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Appendix A
Appendix: Recipes for reagents
prepared in the laboratory
0.2 M citric acid/Na phosphate buffer: 36.85 mL 100 mM citric acid solution,
63.15 mL 200 mM Na phosphate solution
1 x Transfer Buffer: 50 mL 20 x buffer, 100 mL 10% methanol, H2O up to 1 L
20 x buffer: 25 mM Tris, 192 mM Glycine
10% SDS-PAGE Protein Gel:
Resolving gel: 4.2 mL H2O, 2.5 mL lower buffer, 3.3 mL 30% acrylamide,
140 µL
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Stacking gel: 2.35 mL H2O, 1 mL upper buffer, 650 µL 30% acrylamide,
150 µL APS, 20 µL TEMED
10 x Tris Glycine Buffer: 0.25 M Tris, 1.92 M Glycine, 0.25% Sodium dodecyl
sulfate (SDS)
β-galactosidase fixation solution: 5.4 mL 37% formaldehyde, 0.8 mL 25%
glutaraldehyde, 93.8 mL PBS
β-galactosidase staining solution: 5 mL 40 mM citric acid/Na phosphate
buffer, 1.25 mL 5 mM K4[Fe(CN)6]3H3O, 1.25 mL 5 mM K3[Fe(CN)6], 750
µL 150 mM sodium chloride, 50 µL 2 mM magnesium chloride and 1.25 mL
20 mg/mL X-gal, 15.45 mL distilled water
Blocking buffer: 5% skim milk powder, 0.5% Tween-20 in PBS
Crystal violet fix: 10% acetic acid, 10% methanol
Crystal violet fix: 0.5 g crystal violet powder, 80 mL H2O, 20 mL methanol
Loading Dye: 750µL loading buffer protein, 250 µL β-mercapto-ethanol
Lower buffer: 1.5 M Tris (pH 8.8), 0.4% SDS
PBS: 1 x PBS tablet dissolved in 100 mL mQH2O
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Soft Agar assay stain: 0.01% Crystal violet, 10% Ethanol
RIPA buffer: 25 mM Tris, 15 0mM sodium chloride, 0.1% SDS, 0.5% sodiun
deoxycholate, 1% Triton X 100
TBS-Tween: 50 mM Tris, 150 mM NaCl, 0.0% Tween-20 (pH 7.6)
Upper buffer: 0.5 M Tris-Cl (pH 6.8), 0.4 % SDS
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Appendix B
Appendix: qPCR standard curves
and probe efficiencies
Representative qPCR standard curve for the gene of interest ARMT1
in MCF-7 cells. Untreated MCF-7 cells were used to create standard cDNA.
Standard curve was created using triplicates of known dilution concentrations.
The efficiency calculated for probe was 96.51%. Any samples with a Cq >35 were
not included.
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Representative qPCR standard curve for the gene of interest CCDC170
in MCF-7 cells. Untreated MCF-7 cells were used to create standard cDNA.
Standard curve was created using triplicates of known dilution concentrations.
The efficiency calculated for probe was 92.48%. Any samples with a Cq >35 were
not included.
Representative qPCR standard curve for the gene of interest ESR1
in MCF-7 cells. Untreated MCF-7 cells were used to create standard cDNA.
Standard curve was created using triplicates of known dilution concentrations.
The efficiency calculated for probe was 99.26%. Any samples with a Cq >35 were
not included.
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Representative qPCR standard curve for the gene of interest RMND1
in MCF-7 cells. Untreated MCF-7 cells were used to create standard cDNA.
Standard curve was created using triplicates of known dilution concentrations.
The efficiency calculated for probe was 99.47%. Any samples with a Cq >35 were
not included.
Representative qPCR standard curve for the gene of interest GREB1
in MCF-7 cells. Untreated MCF-7 cells were used to create standard cDNA.
Standard curve was created using triplicates of known dilution concentrations.
The efficiency calculated for probe was 94.61%. Any samples with a Cq >35 were
not included.
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Representative qPCR standard curve for the gene of interest TFF1
in MCF-7 cells. Untreated MCF-7 cells were used to create standard cDNA.
Standard curve was created using triplicates of known dilution concentrations.
The efficiency calculated for probe was 107.50%. Any samples with a Cq >35 were
not included.
Representative qPCR standard curve for the gene of interest FKBP15
in MCF-7 cells. Untreated MCF-7 cells were used to create standard cDNA.
Standard curve was created using triplicates of known dilution concentrations.
The efficiency calculated for probe was 94.30%. Any samples with a Cq >35 were
not included.
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Representative qPCR standard curve for the gene of interest PUM1
in MCF-7 cells. Untreated MCF-7 cells were used to create standard cDNA.
Standard curve was created using triplicates of known dilution concentrations.






Western blot showing HA-tagged proteins. Subsequent Western Blot show-
ing HA-tagged proteins and tubulin loading control. 20 ng of extracted protein
from each clone was separated on SDS-PAGE and transferred to a nitrocellulose
membrane, then incubated with antibodies to detect HA-tag then tubulin.
Western blot showing HA-tagged proteins. Subsequent Western Blot show-
ing HA-tagged proteins and tubulin loading control with quantified band strength.
20 ng of extracted protein from each clone was separated on SDS-PAGE and trans-
ferred to a nitrocellulose membrane, then incubated with antibodies to detect HA-
tag then tubulin. To quantify protein expression, band intensity was measured
using Li-Cor Odyssey R© Fc Imaging System FieldBriteTM XT software and nor-
malised to the HA-3 sample.
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Western blot showing HA-tagged proteins. Subsequent Western Blot show-
ing HA-tagged proteins and tubulin loading control. 20 ng of extracted protein
from each clone was separated on SDS-PAGE and transferred to a nitrocellulose
membrane, then incubated with antibodies to detect HA-tag then tubulin.
Western blot showing HA-tagged proteins. Subsequent Western Blot show-
ing HA-tagged proteins and tubulin loading control with quantified band strength.
20 ng of extracted protein from each clone was separated on SDS-PAGE and trans-
ferred to a nitrocellulose membrane, then incubated with antibodies to detect HA-
tag then tubulin. To quantify protein expression, band intensity was measured
using Li-Cor Odyssey R© Fc Imaging System FieldBriteTM XT software and nor-




D.1 Clonogenic IC50 graphs
Graph of clonogenic IC50 in doxorubicin treated ARMT1 knockdown
clones and controls. Doxorubicin treatment values were logged, then the data
fit to a nonlinear regression curve of log(inhibitor) vs. response.
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Graph of clonogenic IC50 in doxorubicin treated ARMT1 overexpres-
sion clones and control. Doxorubicin treatment values were logged, then the
data fit to a nonlinear regression curve of log(inhibitor) vs. response.
Graph of clonogenic IC50 in UV treated ARMT1 knockdown clones
and controls. UV treatment values were logged, then the data fit to a nonlinear
regression curve of log(inhibitor) vs. response.
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Graph of clonogenic IC50 in UV treated ARMT1 ovexpression clones
and control. Uv treatment values were logged, then the data fit to a nonlinear
regression curve of log(inhibitor) vs. response.
D.2 Non clonogenic IC50 graphs
Graph of non clonogenic IC50 in doxorubicin treated ARMT1 knock-
down clones and controls. Doxorubicin treatment values were logged, then the
data fit to a nonlinear regression curve of log(inhibitor) vs. response.
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Graph of non clonogenic IC50 in doxorubicin treated ARMT1 overex-
pression clones and control. Doxorubicin treatment values were logged, then
the data fit to a nonlinear regression curve of log(inhibitor) vs. response.
Graph of non clonogenic IC50 in UV treated ARMT1 knockdown clones
and controls. UV treatment values were logged, then the data fit to a nonlinear
regression curve of log(inhibitor) vs. response.
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Graph of non clonogenic IC50 in UV treated ARMT1 ovexpression
clones and control. Uv treatment values were logged, then the data fit to a
nonlinear regression curve of log(inhibitor) vs. response.
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